Literature DB >> 26913599

The miR-27a-calreticulin axis affects drug-induced immunogenic cell death in human colorectal cancer cells.

T Colangelo1, G Polcaro1, P Ziccardi1, L Muccillo1, M Galgani2, B Pucci3, M Rita Milone3, A Budillon3, M Santopaolo4, G Mazzoccoli5, G Matarese2,4, L Sabatino1, V Colantuoni1.   

Abstract

Immunogenic cell death (ICD) evoked by chemotherapeutic agents implies emission of selected damage-associated molecular patterns (DAMP) such as cell surface exposure of calreticulin, secretion of ATP and HMGB1. We sought to verify whether miR-27a is implicated in ICD, having demonstrated that it directly targets calreticulin. To this goal, we exposed colorectal cancer cell lines, genetically modified to express high or low miR-27a levels, to two bona fide ICD inducers (mitoxantrone and oxaliplatin). Low miR-27a-expressing cells displayed more ecto-calreticulin on the cell surface and increased ATP and HMGB1 secretion than high miR-27a-expressing ones in time-course experiments upon drug exposure. A calreticulin target protector counteracted the miR-27a effects while specific siRNAs mimicked them, confirming the results reported. In addition, miR-27a negatively influenced the PERK-mediated route and the late PI3K-dependent secretory step of the unfolded protein response to endoplasmic reticulum stress, suggesting that miR-27a modulates the entire ICD program. Interestingly, upon chemotherapeutic exposure, low miR-27a levels associated with an earlier and stronger induction of apoptosis and with morphological and molecular features of autophagy. Remarkably, in ex vivo setting, under the same chemotherapeutic induction, the conditioned media from high miR-27a-expressing cells impeded dendritic cell maturation while increased the secretion of specific cytokines (interleukin (IL)-4, IL-6, IL-8) and negatively influenced CD4(+) T-cell interferon γ production and proliferation, all markers of a tumor immunoevasion strategy. In conclusion, we provide the first evidence that miR-27a impairs the cell response to drug-induced ICD through the regulatory axis with calreticulin.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26913599      PMCID: PMC4849155          DOI: 10.1038/cddis.2016.29

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


Normal cells culminate their life span with a death process that has been proposed to occur in at least three major types. Apoptosis is a well-defined process of programmed cell death that includes both an extrinsic and intrinsic pathway and is characterized by cell shrinkage and fragmentation of cellular components including DNA that leads to the formation of apoptotic bodies efficiently cleared by phagocytes. Necrosis usually occurs in pathological circumstances and is characterized by disruption of the cell membrane, swelling of the cytoplasm, breakdown of mitochondria and DNA degradation. All cellular components are released in the extracellular environment where they act as danger signals to promote inflammation.[1, 2, 3] Autophagy is primarily an evolutionarily conserved pathway involving the degradation of cellular components. In detail, autophagy is initiated with the formation of autophagosomes engulfed with cytosolic materials, fusion with lysosome to form autolysosomes followed by degradation to simple components to meet the energetic and anabolic needs of the cell. Autophagy is then a stress response system required for survival, although in cancer it has a dual role acting either as a tumor suppressor or an oncogene in a context-dependent manner.[3, 4] Apoptotic, necrotic and autophagic tumor cells release damage-associated molecular patterns (DAMP) which are recognized by receptors on the surface of immune cells largely determining whether cell death is immunogenic (immunogenic cell death, ICD) or tolerogenic (tolerogenic cell death).[5, 6] This topic is gaining increasing moment in anticancer therapy as resistance to apoptotic cell death has been recognized as a major hallmark of cancer affecting the tumor phenotype and its progression. Specifically, a selected class of chemotherapeutic agents (anthracyclines and radiations) elicit an active anti-tumor response through emission of DAMPs such as ecto-calreticulin, ATP and HMGB1 secretion in a process defined drug-induced ICD that is part of the cellular unfolded protein response (UPR) to endoplasmic reticulum (ER) stress stimuli.[5, 6, 7, 8] Once exposed, in addition to apoptosis and/or autophagy, DAMPs serve as signals to facilitate the engulfment of dying cells by macrophages and dendritic cells (DCs), leading to the activation of a potent anticancer immunity.[9] Among the emitted DAMPs, calreticulin is gaining interest because of its pleiotropic functions: it acts, in fact, as an ER chaperone, is implicated in the protein-loading complex to assemble the mature MHC class I molecules on the cell surface, activates the apoptotic pathway and, upon ICD inducer administration, translocates to the cell surface where it acts as an ‘eat me' signal to mount an efficient immune response. Reduction of ecto-calreticulin exposure greatly impairs the apoptotic pathway and the immune response in vitro and in vivo.[11, 12] microRNA dysregulation is a common feature of human malignancies as they act as onco-miRNAs or tumor suppressor miRNAs; their implication in the immune response is under active investigation.[13, 14, 15] We have identified miR-27a as one of the upregulated miRNAs in CRC and proved that it acts as an oncomiRNA as it is already overexpressed in adenomas and further increases during tumor progression.[16] miR-27a is a member of the miR-23a, miR-27a and miR-24-2 cluster and is acquiring a growing regulatory role because it is implicated in multiple processes including tumorigenesis.[17, 18] We have also demonstrated that calreticulin is a direct target of miR-27a and mediates MHC class I molecules expression.[16] We sought to verify whether miR-27a can modulate the events related to cell death and drug-induced ICD. Here, we provide evidence that miR-27a impairs the kinetics of calreticulin surface exposure along with ATP and HMGB1 secretion following mitoxantrone or oxaliplatin treatment. A selective calreticulin target protector counteracted while specific siRNAs mimicked the miR-27a-specific effects supporting the pivotal role played by this protein. miR-27a hampered the cellular UPR route following exogenous ER stress stimuli. Finally, miR-27a impaired the apoptotic and autophagy pathways, suggesting that it is a master regulator in determining cell fate. In ex vivo setting, under the same chemotherapeutic induction, the conditioned media (CM) from high miR-27a-expressing cells impeded DC maturation while increased secretion of specific cytokines (interleukin (IL)-4, IL-6, IL-8) and negatively influenced CD4+ T-cell interferon γ production and proliferation, markers of a tumor immunoevasion strategy.

Results

miR-27a down-modulates emission of DAMPS upon ICD inducers

Cell death is the most enriched pathway in the Ingenuity Pathway Analysis generated from the list of differentially expressed proteins (red elements=upregulated proteins; green elements=downregulated proteins) after miR-27a silencing in HCT116 cells (Figure 1a).[16] Having shown that calreticulin is a target of miR-27a[16] and given its pivotal role also in ICD, we assessed the effects of miR-27a on ecto-calreticulin, ATP and HMGB1 release (i.e., DAMPs emission) from dying cells undergoing anticancer drug-induced ICD.[4, 6, 10, 19] We exposed HCT116 CRTL, miR27a_KD and miR27a_OE cells to the anthracycline mitoxantrone (MTX, 1 μM) or oxaliplatin (OXP, 100 μM), two bona fide ICD inducers, in time-course experiments and DAMPs exposure/release was analyzed. In flow cytometry, both drugs induced a slow but significant calreticulin translocation to the cell surface in HCT116 cells, that was modest in miR27a_KD and even less evident in miR27a_OE cells, likely owing to the silenced or forced miR-27a expression, respectively, coupled with the fact that calreticulin is a miRNA direct target (Figure 1b and Supplementary Figure S1A). These results were confirmed by immunofluorescence staining of non-permeabilized cells, showing the typical ‘patches' of ecto-calreticulin, especially in miR27a_KD, and analysis of the isolated plasma membrane fraction (Figures 1c and d).[12, 20] Of note, also the secreted calreticulin, already present in basal conditions, increased, especially in miR27a_KD, in line with its higher plasma membrane content, indicating that miR-27a also modulates calreticulin secretion (Figure 1e). We also evaluated two additional DAMP (ATP and HMGB1) release during drug-induced ICD.[19, 21] The kinetics of ATP release in the cell culture media showed that cells with a silenced miR-27a were more responsive to both drugs and secreted higher amounts of ATP; opposite results were obtained in cells overexpressing miR-27a (Figure 2a). Intracellular ATP mirrored the extracellular amount in all cell lines investigated (Supplementary Figure S1B). Finally, time-course of HMGB1 release evidenced in miR27a_KD that the protein, already secreted in basal conditions, slightly increased upon exposure to both drugs; in HCT116 CTRL, the increase was delayed, even further in miR27a_OE cells (Figures 2b and d).
Figure 1

Calreticulin cell surface exposure is downregulated by miR-27a. (a) Cell deaths were the most enriched networks in the Ingenuity Pathway Analysis generated from the list of differentially expressed proteins (red elements=upregulated proteins; green elements=downregulated proteins) after miR-27a silencing in HCT116 cells.[16] (b) Cell-surface calreticulin (CRT) assessed by flow cytometry or (c) immunofluorescence staining or (d) western blot in the isolated plasma membrane fraction from HCT116 CRTL, miR27a_KD and miR27a_OE cells exposed to mitoxantrone (MTX, 1 μM) or oxaliplatin (OXP, 100 μM) for 12 h. (CRT=red; nuclei=blue; GFP=green as a marker). The white arrow indicates the patches of ecto-CRT. (Scale bar, 5 μm). Positivity for E-cadherin, a plasma membrane protein, proved that the identified proteins were truly integral membrane components in (d). Immuno-detection of extracellular CLR in the culture media of HCT116 CRTL, miR27a_KD and miR27a_OE. The histogram shows the relative quantification of the bands. Samples were analyzed in triplicate and data are mean±S.D. and representative of three experiments in (b, d). *P⩽0.05; **P⩽0.01 (two-tailed Student's t-test)

Figure 2

miR-27a affects the kinetics of emission/release of DAMPs upon chemotherapeutic-mediated ICD. (a) Kinetics of induction of ATP secretion in HCT116 CRTL, miR27a_KD and miR27a_OE cells exposed to MTX (1 μM) or OXP (100 μM). (b) Immuno-detection of intracellular and extracellular HMGB1 in HCT116 CRTL, miR27a_KD and miR27a_OE cells; the quantification of the bands is illustrated in the corresponding histograms. (c) Time-course of HMGB1 secretion upon exposure of HCT116 CRTL, miR27a_KD and miR27a_OE cells to either MTX or OXP quantified as reported in the histograms in (d). All values are mean±S.D. of three independent experiments. *P⩽0.05; **P⩽0.01 (two-tailed Student's t-test)

The kinetics of DAMP emission upon MTX or OXP administration was investigated in an additional CRC-derived cell line (RKO) and the derived miR27a_KD and miR27a_OE cell clones having miR-27a silenced or overexpressed, respectively. An earlier and robust calreticulin translocation to the cell membrane was detected in miR27a_KD, slower and marginal in miR27a_OE and intermediate in parental RKO cells. Also, the time-course of ATP and HMGB1 release showed the same behavior with a response that was inversely related to miR-27a levels (Supplementary Figures S2A and C). That similar results were obtained with two distinct drugs in different CRC cell lines indicates that miR-27a modulation of DAMP emission following chemotherapeutic stimulation is a general phenomenon and that, according to its levels, miR-27a sensitizes the cells finely tuning the response. The central role that calreticulin has in this pathway was further demonstrated in transfection assays with a specific target protector: a marked enrichment of the protein was detected on the surface of HCT116 CTRL and miR27a_OE, likely owing to higher miR-27a levels (Supplementary Figures S3A and B). In contrast, transfection of three independent siRNAs reduced ecto-calreticulin in all cells, in proportion to the different protein content, as reported.[16] Interestingly, transfection of calreticulin target protector stimulated secretion of ATP and HMGB1 in HCT116 and miR27a_OE cells, while the specific siRNAs reduced secretion of both compounds in all cell lines (Supplementary Figures S3C and D).

miR-27a dictates the decision between cell death and survival

Antitumor agent-induced ICD is associated with the activation of programmed cell death pathways.[2, 6] To verify that miR-27a influences apoptosis, we performed time-course experiments of MTX treatment on HCT116 and derived clones. Both the cleaved forms of PARP and caspase 3, already detectable in basal conditions in miR27a_KD, further increased starting from earlier times with respect to HCT116 and miR27a_OE in which the increase was delayed (Figures 3a and b). Similar results were obtained in RKO and corresponding clones (Supplementary Figure S4A). Time-course experiments were also carried out with OXP in both cell lines and derived clones. By flow cytometry, low miR-27a-expressing cells displayed an increase of the pre-apoptotic (annexin V-PE+ and 7-AAD−) and apoptotic (annexin V-PE+ and 7-AAD+) cell populations at earlier times than high miR-27a-expressing ones (Figure 3c and Supplementary Figure S4B).
Figure 3

miR-27a impairs the kinetics of apoptosis execution in drug-induced ICD. (a) Western blot analysis of the apoptosis markers, PARP and caspase 3, in time-course experiments of HCT116 CRTL, miR27a_KD and miR27a_OE cells treated or not with mitoxantrone (1 μM). β-Actin was used as loading control and quantification of the cleaved protein forms is reported in (b). (c) Flow cytometry analysis of pre-apoptotic (annexin V-PE+ and 7-AAD-) and apoptotic (annexin V-PE+ and 7-AAD+) HCT116 CRTL, miR27a_KD and miR27a_OE cells treated with OXP (100 μM) in kinetics experiments. One representative experiment out of three is shown

ATP and HMGB1 release and ecto-calreticulin exposure have been associated with execution of autophagy.[7, 22, 23] In miR27a_KD cells, this pathway is already active in basal conditions as documented by the presence of the mature LC3-II form and acquisition of autophagic morphological features (large bodies, multiple or multilobated nuclei, cytosolic vacuoles and granules) with respect to HCT116 CTRL and miR27a_OE cells (Figures 4a and b). MTX administration induced autophagy in time-course experiments, as the mature LC3-II form rapidly increased in miR27a_KD and only scantly in HCT116 and miR27a_OE cells (Figure 4c). To verify that the higher LC3-II levels reflect an increased autophagic flux that culminates into the formation of autophagosomes, we tested the effects of the lysosomotropic agent, chloroquine. The mature LC3-II form showed a remarkable dose-dependent increase in miR27a_KD with respect to parental and even more than miR27a_OE cells (Figure 4b).
Figure 4

miR-27a knockdown promotes autophagy in CRC cells. (a) Morphological features of HCT116 CRTL, miR27a_KD and miR27a_OE cells were evaluated by hematoxylin and eosin staining; the arrows point out some remarkable phenotypic characteristics (Scale bar, 20 mm). (b) Dose-dependent induction of autophagy in HCT116 CRTL, miR27a_KD and miR27a_OE cells exposed to the lysosomotropic drug chloroquine (CQ). Western blot analysis of the LC3-II mature form, an autophagic marker, is reported along with its relative quantification in the histogram. β-Actin was used as loading control. (c) Time-course of autophagy induction in HCT116 CRTL, miR27a_KD and miR27a_OE cells upon MTX treatment at 1 μM. Immunoblot of LC-3-II was used as a marker. All data are representative of three independent experiments and error bars represent S.D. of technical replicates (mean±S.D.)

miR-27a hampers the chemotherapeutic-induced ICD through the same route of the UPR

Next, we asked whether miR-27a impairs drug-elicited ICD through the same route of the UPR that is activated in response to ER stimuli. ICD is, in fact, executed through activation of the double-stranded RNA-activated protein kinase-like ER kinase (PERK)-governed arm of the UPR and the PI3K-dependent secretory pathway.[1, 8, 24, 25, 26] The kinetics of activation of this pathway was assessed: upon treatment, phosphorylation of PERK and its downstream factor eIF2a, already high in miR27a_KD cells, further increased; in miR27a_OE, phosphorylation was lower and delayed with respect to HCT116 CRTL cells (Figure 5a). GRP78, another protein associated with ER stress induction, showed no significant variations with respect to the differential basal levels (Figure 5a). The other two arms of the UPR were tested and found not affected, as previously reported[8] (our data not shown). The ability of miR-27a to modulate the PI3K-dependent late secretory step was proved by assessing the amount of ecto-calreticulin in the plasma membrane fraction before and after administration of the PI3K inhibitor LY-294002 alone or in combination with MTX. Phosphorylation of AKT, a protein target of PI3K, was almost undetectable in HCT116 and derived clones demonstrating the efficacy of the treatment (Supplementary Figure S5A). LY-294002 caused a remarkable impairment of calreticulin plasma membrane translocation in miR27a_KD, less evident in HCT116 and miR27a_OE cells, likely owing to the higher miR-27a levels. The combined treatment did not rescue ecto-calreticulin in all cells (Figure 5b). Collectively, miR-27a affects the magnitude of DAMP emission in response to MTX through the same UPR route, according to its endogenous levels.
Figure 5

miR-27a counteracts mitoxantrone-induced ICD through the same UPR pathway. (a) Immunoblot analysis of PERK, p-PERK, eIF2α, p-eIF2α and GRP78 in time-course experiments of HCT116 CRTL, miR27a_KD and miR27a_OE cells treated with 1 μM MTX; phosphorylation was referred to equivalent amounts of the non-phosphorylated forms of the proteins in all cells and then to β-actin used as a loading control. Quantification of the bands in basal and in the kinetic conditions is reported. (b) CRT cell surface expression in HCT116 CRTL, miR27a_KD and miR27a_OE cells untreated or treated for 12 h with 20 mM LY-294002, alone or in combination with 1 μM MTX for the last 6 h. Densitometric analysis was carried out after normalization to E-cadherin. *P⩽0.05; ** P⩽0.01 (two-tailed Student's t-test) versus HCT116 CRTL cells; #P⩽0.05; ##P⩽0.01 (two-tailed Student's t-test) versus MTX-untreated cells. The values are representative of five experiments

miR-27a in CRC cells influences DC maturation, proliferation and IFN-γ production by CD4+ T cells in ex vivo experiments

We investigated whether miR-27a affects the ability of DAMPs emitted in response to chemotherapeutics to act as immunogenic signals towards monocyte-derived immature DCs prompting their maturation.[4, 6, 27] HCT116 cells were transiently transfected with a specific miR-27a mimic (S), antisense (AS) or scrambled control RNA (C), treated with MTX or OXP for the last 12 h and co-cultured with human immature DCs (hu-iDCs) for further 20 h (Figure 6a). In flow cytometry experiments, expression of the DC maturation antigens (MHC class II/CD86; CD80/CD83)[19] increased in co-cultures of hu-iDCs with AS-transfected and treated tumor cells with respect to S- or C-transfected and treated cells. Stimulation of DCs with lipopolysaccharide was used as the positive control (Figure 6b). Similar results were obtained with co-cultures of hu-iDCs with transfected and treated RKO cells (Supplementary Figure S5B) and with HCT116 and RKO stable-derived clones (data not shown). The CM from S-, AS- or C-transfected cells alone or from co-cultures with hu-iDCs were assessed for a cytokine array (Figure 6c). IL-8 was detected in the CM from S-transfected cells alone and co-cultures with S- and C-transfected cells indicating that it was related to miR-27a expression levels. IL-4 was only detected in the co-cultures media, in particular in those from S- and C-transfected HCT116 cells. In addition, IL-6 was found only in the CM from co-cultures with S-transfected HCT116 cells (Figure 6d). As engulfment of mature DCs with dying tumor cells is able to mount an active immune response,[6, 19] the CM from AS-transfected HCT116 cells were tested and found to stimulate proliferation of naive freshly isolated CD4+ T cells more than those from S- or C-transfected cells (Figure 7a). The induction was stronger in T-cell receptor stimulated (anti-CD3/anti-CD28) CD4+ T cells displaying the same correlation with miR-27a levels.[28] The CMs from co-cultures of hu-iDCs with the same cells pretreated with MTX or OXP exhibited the same trend either on unstimulated and T-cell receptor-stimulated CD4+ T cells (Figure 7b). Finally, the CMs from co-cultures of hu-iDCs with AS-transfected and pretreated cells promoted higher IFN-γ production from unstimulated CD4+ T cells than CMs from co-cultures of C- and remarkably S-transfected cells; as expected, the effect was stronger in T-cell receptor-stimulated CD4+ T cells (Figure 7c). Taken together, these results indicate that, in response to antitumor drugs, miR-27a in CRC cells impairs immunogenic signal emission and DC maturation, whereas stimulates secretion of cytokines associated with CRC progression,[29, 30, 31] influences activation and IFN-γ production from CD4+ T cells suggesting a possible role in eliciting an active immune response.
Figure 6

miR-27a in CRC cells modulates monocyte-derived human DCs maturation and secretion of selected cytokines upon drug-mediated ICD. (a) Scheme of the experimental setting: hu-iDCs were generated from filtered buffy coat-derived monocytes donated by healthy donors and grown for 5/6 days in the presence of specific stimulatory factors. Hu-iDCs were identified by FACS analysis of CD1a+ cells, counted and co-cultured (1 : 2 ratio) with HCT116 or RKO cells previously transfected for 72 h with a miR-27a synthetic mimic (S), AS or scrambled control (C) RNA, respectively, and treated for the last 12 h with OXP (100 μM). (b) Flow cytometry analysis of specific DC maturation markers (CD86+/HLA-DR+, CD80+/CD83+) upon 20 h of co-cultures as described in (a); lipopolysaccharide stimulation (0.1 mg/ml) of hu-iDCs was used as positive control of DC maturation. Only the results with OXP treatment are reported, similar results were obtained with MTX. The histogram illustrates the results of five experiments. (c) A cytokine ELISA array was performed on the CM from S-, AS- or C-transfected HCT116, alone or from co-cultures of the same cells with hu-iDCs; the color-code reports the range of values of the cytokines detected. (d) The histogram shows quantification of IL-8, IL-4 and IL-6 detected with the cytokine ELISA array. Samples were analyzed in triplicate and data are mean±S.D. and representative of three experiments. *P⩽0.05; **P⩽0.01 (two-tailed Student's t-test)

Figure 7

miR-27a influences proliferation and IFN-γ production by CD4+ T cells in ex vivo experiments upon drug-mediated ICD. The CM from S-, AS- or C-transfected and treated HCT116 alone (a) or from co-cultures of the same transfected and pretreated cells cells with hu-iDCs (b) were added to naïve, freshly isolated CD4+ T cells either unstimulated or stimulated with anti-CD3/CD28 dynabeads to test their ability to proliferate. Samples were analyzed in triplicate and data are mean±S.D. and representative of three experiments. *P⩽0.05 (two-tailed Student's t-test). (c) To analyze the production of IFN-γ, freshly isolated CD4+ T cells were cultured overnight in the presence or absence of anti-CD3/CD28 dynabeads and exposed to CMs from co-cultures as in (b). Samples were analyzed in triplicate and data are mean±S.D. and representative of three experiments. *P⩽0.05; **P⩽0.01 (two-tailed Student's t-test)

Discussion

Living organisms retain their homeostasis through a finely tuned balance between cell proliferation and death. Multiple modes of cell death exist in nature, and apoptosis or type 1 programmed cell death is likely the most frequent both in normal and tumor cells and characterized by typical morphological changes.[1, 2, 3] Apoptosis has also been considered as a non-ICD mechanism, although in the past years, this concept has been revised: in fact, several anti-neoplastic drugs such as anthracyclines, oxaliplatin or hypericin-based photodynamic therapy and oncolytic coxsackievirus B3 (CVB3) trigger immunogenic apoptosis.[32, 33] This conceptual change stems from the observation that apoptotic cancer cells treated with these chemotherapeutics or radiotherapy release a series of DAMPs that could provoke an immune response.[8, 9, 10, 34] The hallmarks of ICD are calreticulin cell surface exposure, ATP and HMGB1 secretion. Here, we provide evidence that in CRC-derived cell lines exposed to two different bona fide ICD inducers (mitoxantrone and oxaliplatin), the amount of calreticulin translocated onto the cell surface is greatly impaired in cells overexpressing miR-27a, and heightened in miR-27a-silenced cells. We have recently identified calreticulin as a direct target of miR-27a and the effect reported here is the result of such modulation.[16] The effect appears to be highly specific as a calreticulin target protector or specific siRNAs produce similar results, supporting the central role that the protein has in this pathway in line with data from the literature.[11, 12, 35] Interestingly, high miR-27a-expressing cells exhibit reduced ATP secretion and HMGB1 release; whether these effects are due to the control of miR-27a or other still uncovered genes or non-coding RNAs is not known at the moment. We demonstrate that their secretion parallel ecto-calreticulin exposure with a similar early and strong induction in conditions of low miR-27a levels, suggesting that miR-27a silencing sensitizes the cells, tuning the response to chemotherapeutic agents.[35, 36] That miR-27a modulates the entire ICD program is further supported by the investigation of the UPR route. ICD is, in fact, executed through activation of the PERK-governed arm and the PI3K-dependent secretory pathway of the UPR to ER stress.[1, 24, 25, 26] We show that miR-27a greatly impairs the entire pathway especially the late secretory module; silencing the microRNA rescues the entire arm, suggesting that ATP and/or HMGB1 secretion might be regulated through the same route as previously suggested;[4] elucidation of this topic, however, requires deeper and more targeted experiments. High miR-27a-expressing cells display enhanced cell growth and survival potential, whereas its silencing stimulates the apoptotic pathway, indicating that miR-27a dictates the cell decision between survival and death in vitro and in mouse xenografts supporting the conclusion that miR-27a acts as an oncomiRNA.[16] Remarkably, we find that miR-27a inversely modulates also autophagy and that, in our cell model, apoptosis and autophagy operate in the same direction.[3, 4] As ATP and HMGB1 have been associated with execution of autophagy, collectively, our data are consistent with an overall ICD process repression influenced by miR-27a. DAMP emission has been associated with the ability to elicit an efficient immune response. In fact, ecto-calreticulin acts as an ‘eat me' signal, secreted ATP as a ‘find me ‘ signal and released HMGB1 as a docking site for TLR and other receptors on the surface of dendritic and phagocytic cells.[5, 7] We demonstrate here in ex vivo experiments that CRC cells expressing low levels of miR-27a subject to drug-induced ICD elicit efficient maturation of DC cells and cytokine secretion, induce proliferation of CD4+ T cells and INF-γ secretion, all markers of immune activation. Full validation of an efficient anti-tumor response requires experiments in immunocompetent mice models; nonetheless, the analysis of our series of sporadic CRCs shows that high miR-27a-expressing tumors associate with reduced ecto-calreticulin, CD3+ and CD8+ infiltration and activity.[16] Interestingly, the combination high miR-27a/low calreticulin is linked to liver metastasis and a worse prognosis, further implying the role that the miR-27a-calreticulin axis may have in stimulating the immune system and thus in the overall survival of CRC patients.[16] Of note, calreticulin seems to be the dominant determinant in this analysis.[35, 36] Our data are supported by a recent study in which a reduced level of calreticulin in a naturally occurring cancer cell model is the primary, if not the only reason, to explain resistance to anticancer vaccination. Moreover, calreticulin levels are predictive of patient clinical responses to ICD-inducing anticancer therapies with possibly clinical implications. In this ICD clinical setting, calreticulin positively correlates with the expression of phagocytosis-associated genes relevant for phagosome maturation/processing.[9] The existence of mechanisms of resistance to anticancer vaccination effect represents a major obstacle for antitumor immunotherapy, so that their identification could explain the failure of certain subsets of patients in responding to ICD inducers.[9] The results we present here unveil miR-27a as a negative regulator of the drug-induced ICD response by downregulating calreticulin expression and cell surface exposure. Calreticulin, thus, has a critical position at the interface between cancer cells and the immune system.[12, 35, 36] The disclosure of the miR-27a-calreticulin axis and its role in ICD may pave the way for future research aimed to stratify CRC patients on the basis of miR-27a/calreticulin expression levels and design novel personalized therapeutic interventions.

Materials and Methods

Cell culture

Human colon cancer cell lines HCT116 and RKO were purchased from American Type Culture Collection (ATCC, Rockville, MD, USA) and cultured as reported.[37]

Oligonucleotides and plasmid transfection

Synthetic miR-27a mimic (Syn-hsa-miR-27a), miR-27a inhibitor (anti-hsa-miR-27a) or the appropriate scrambled controls (AllStar or mirScript Inhibitor-Negative Control) were purchased from Qiagen (Hilden, Germany). The miR-27a-antisense (MZIP27a-PA-1), the pre-miR-27a expression constructs (PMIRH27a-onlyPA-1) and scrambled control miRNAs (MZIP000-PA-1; PMIRH000PA-1) plasmids (System Biosciences, Mountain View, CA, USA) were transfected in the different CRC cell lines. microRNA functional studies were performed by inhibiting miRNA-mRNA target interactions either with a custom-designed calreticulin-miScript Target Protector or a negative control miScript Target Protector (MTP0075035; Qiagen). Detection of no variations in unrelated proteins validated target protector specificity. A gene-specific package of three preselected siRNAs against calreticulin (Flexi Tube siRNA GS811) or a negative control siRNA (SI03650325) (Qiagen) was used in transient transfections. Functional assays, RNA and protein analyses were performed within 24/72 h from transfections. In each experiment, the extent of miR-27a silencing/overexpression was assessed by qRT-PCR. Plasmids and oligonucleotides were transfected using Lipofectamine 2000 (Thermo Fisher, Waltham, MA, USA) and HiPerFect Transfection Reagent (Qiagen) or RNAi Max (Thermo Fisher), respectively, according to the manufacturers' recommendations.

mRNA/miRNA extraction and qRT-PCR analysis

Total RNA was extracted from cells and tissues using TRIzol (Thermo Fisher) and treated with DNase I. microRNAs were extracted using the Qiagen miRNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. Assessment of RNA purity and quantity was performed as described.[37]

Western blot analysis

Protein extracts from cell lines and tissues were prepared and analyzed as previously reported.[37] Antibodies against calreticulin (ab2907), HMGB1 (ab79823) were from Abcam (Cambridge, MA, USA); GRP78 (sc-13968), PERK (sc-377400), p-PERK (sc-32577), Caspase-3 (sc-7148), anti-mouse (sc-2031), anti rabbit (sc-2004) from Santa Cruz Biotechnology (Dallas, TX, USA), LC3 (GTX 82986) from Genetex (Irvine, CA, USA); β-actin (F-3022) from Sigma-Aldrich (Milan, Italy); E-cadherin (BD 610405) from BD transduction (BD Biosciences, San Jose, CA, USA); AKT (Y058027) and p-AKT (Y080084) from abm (Richmond, BC, Canada); eIF2a (#9722), p-eIF2a(#3597) and PARP (#9542 S) from Cell Signaling (Danvers, MA, USA). To analyze surface proteins, we used an extraction method based on a published procedure.[38] Positivity for E-cadherin, a plasma membrane protein, and negativity for β-actin, a cytosolic protein, proved that the identified proteins were truly integral membrane components. Coomassie blue staining was also used for assessing equivalent protein load. In some experiments, the culture medium (2–8 ml) was collected and concentrated to feasible volumes (200–500 μl) via centrifugation (2000 × g for 1 h) through Centricon microconcentrators PLUS 10 KDa filter (Merck-Millipore, Darmstadt, Germany). Proteins were then analyzed by western blot.

Immunofluorescence

Immunofluorescence staining was carried out on non-permeabilized HCT116 or RKO and derivative clones exposed or not to pharmacological treatments. Cells were plated on coverslips, fixed in paraformaldehyde (4% in PBS) at room temperature for 10 min, blocked in bovine serum albumin (3% in PBS) for 30 min before incubation with specific antibodies to calreticulin (1 : 100 dilution) for 1 h at room temperature. Subsequently anti-rabbit-Tritc (GTXRB-003-ERHOX, 1 : 1000 dilution) (Immunoreagent, Raleigh, NC, USA) were incubated for 1 h at room temperature. Coverslips were washed with PBS, stained with DAPI and, after three more washes in cold PBS, mounted in mowiol 4-88 (Merck-Millipore) on glass slides. For negative controls, only secondary antibodies were used in the absence of primary antibodies. The fluorescence signals were observed and captured using a Carl Zeiss LSM700 laser-scanning microscope (Carl Zeiss, Jena, Germany). Hematoxylin and eosin staining of CRC cells was performed and evaluated as previously reported.[37] Image acquisition and analysis were performed on DM100 Leica Photosystem 40.106.206 (Leica, Milan, Italy).

Flow cytometry

Flow cytometry was used to detect calreticulin on the cell surface of HCT116 and RKO and their derivative clones mir27a_KD or mir27a_OE in basal condition, upon MTX or OXP treatment. Briefly, cells were plated, harvested and washed twice with PBS and incubated for 1 h in darkness at 4 °C with a custom PE-Cy-7-labeled anti-CRT, using PE/Cy7 conjugation kit (ab102903; Abcam), as manufacturer's protocol. Cells were then washed and resuspended in cold PBS for FACS analysis. Apoptosis was evaluated by AnnexinV-PE, 7-AAD using the Apoptosis Detection Kit I (BD Biosciences), according to the manufacturer's protocols. All flow cytometry results were analyzed with FACSuite Software v.1.0.5.3841 (BD Biosciences).

Pharmacological treatments

To elicit ICD, cells were treated with 1 μM mitoxantrone (MTX, Sigma-Aldrich) or 100 μM oxaliplatin (OXP, Sigma-Aldrich) two well-known ICD inducers, in time-course experiments. To block the secretory module, cells were incubated with 20 mM LY-294002 (Sigma-Aldrich), a selective PI3K inhibitor, for 12 h alone or in combination with MTX for the last 6 h of the treatment. The efficacy of the treatment was proved by assessing the phosphorylation level of AKT, a downstream target of PI3K. Chloroquine diphosphate salt (CQ, Sigma-Aldrich) was added to the cells at the indicated concentrations and the amount of the mature LC3-II form assessed.

ATP assay

Extracellular and intracellular ATP levels were measured by the luciferin-based ENLITEN ATP Assay (Promega, Madison, WI, USA). The ATP-driven chemoluminescence was recorded on Luminometer TD-20/20 (Promega).

Ex vivo isolation and maturation of human DCs (hu-DC)

DCs were isolated from peripheral blood mononuclear cells, obtained from 30 ml of leukocyte-enriched buffy coat from healthy donors, centrifuged with F Lymphoprep gradient (Axis-Shield PoC AS, Dundee, Scotland); the light density fraction was recovered. Monocytes were purified by FACS-sorting (BD Biosciences) using a phycoerythrin (PE)-anti-CD14+ antibody (BD Biosciences). Cells were then seeded at a concentration of 0.5–1 × 106 cells/ml in RPMI 1640 supplemented with 10% fetal calf serum or 2% human serum (Sigma-Aldrich), 25 mM HEPES and 2 mM glutamine (complete medium) containing 100 ng/ml granulocyte macrophage-colony-stimulating factor (Sigma-Aldrich) and 100 ng/ml IL-4 (Sigma-Aldrich) and cultured for 5–6 days to obtain a population of immature DCs (hu-iDCs), monitoring their morphology and expression of the specific surface marker CD1a. Immature DCs were scraped, counted and co-cultured for 24 h in a 1 : 2 ratio with HCT116 or RKO cells previously transfected for 72 h with a miR-27a synthetic mimic (S), AS or scrambled control (C) RNA and treated with MTX (1 μM) or OXP (100 μM) for the last 12 h. The percentage of mature DCs was assessed by FACS analysis; an aliquot of these cells was exposed to lipopolysaccharide (Sigma-Aldrich) (0.1 mg/ml), a known pathogen-associated molecular pattern-inducing stimulus, as a positive control for DC maturation. For surface marker analysis by flow cytometry, DCs were stained with the following antibodies: PE-cyanine (Cy)-7 anti-CD80, PE anti-CD86, PE-Cy-7 anti-CD83, PE anti-CD1a (all from Becton Dickinson), Allophycocyanin (APC) anti-HLA-DR (Serotec, Raleigh, NC, USA) and analyzed with the BD FACSCanto using Diva software (BD Biosciences). The cells were also stained with the corresponding PE-, PE-Cy-7 or APC-conjugated isotype-matched control antibody from BD Biosciences.

Human cytokine ELISA array

A human cytokine Multi-AnalyteELISArray Kit (Qiagen) was used to estimate cytokine secretion by HCT116 S, AS- or C-transfected cells alone or by co-cultures of the same cells with hu-iDCs. The cytokines list comprises: IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17A, IFN-γ, TNF-α and granulocyte-macrophage colony-stimulating factor. The array was performed according to the manufacturer's instructions. Cytokine levels were measured by evaluating absorbance at 450 nm on a Microplate reader (Tecan Group Ltd., Mannedorf, Switzerland). Sampling was performed in triplicates.

CD4+ T-cell isolation, proliferation and IFN-γ production

After Ficoll hypaque (GE-Healthcare, Pittsburgh, PA, USA) gradient centrifugation, CD4+ T cells were isolated from PBMC by negative selection using human CD4+ CD25+ T cell kit (Thermo Fisher) (cell purity>98% by FACS analysis) and cultured (1 × 106 cells/ml) in 96-well plates (BD Biosciences) with RPMI 1640 medium supplemented with 100 UI/ml penicillin, 100 μg/ml streptomycin (Thermo Fisher) and supplemented with 5% FCS (Thermo Fisher). Cells were stimulated for 3 days with an anti-CD3/CD28 Dynabeads (0.1 bead/cell) (Thermo Fisher) in the presence or absence of the CM obtained either from co-cultures, as reported above, or from HCT116 or RKO cells transfected with the miR-27a S, AS or C RNA and treated with MTX or OXP. On the last day, cells were exposed to [3H] thymidine (0.5 μCi/well) (GE Healthcare) and harvested 12 h later. Radioactivity was measured with a β-cell-plate scintillation counter (Wallac, Waltham, MA, USA).[39] To analyze the production of IFN-γ, freshly isolated CD4+ T cells were cultured overnight in the presence or absence of anti-CD3/CD28 beads (0.1 beads/cell). To avoid cytokine extracellular export, the cultures were incubated in the presence of 5 μg/ml of Brefeldin-A (Sigma-Aldrich), as previously described.[40] To assess the intracellular production of IFN-γ (Becton Dickinson), cells were treated with a fixing/permeabilization kit (Caltag, Burlingame, UK), following the manufacturer's instructions. CD4+ T cells were stained with APC mouse anti-human IFN-γ and analyzed with the BD FACSCanto using Diva software (Becton Dickinson).

Statistics

All statistical analyses were performed using Statistical Package from Social Science (SPSS; version 16.0) for Windows (SPSS Inc, Chicago, IL, USA) and R/Bioconductor (Seattle, WA, USA). Data are reported as means±S.D., and mean values were compared using the Student's t test. Results were considered statistically significant when P⩽ 0.05 was obtained.
  40 in total

Review 1.  MicroRNAs in cancer: biomarkers, functions and therapy.

Authors:  Josie Hayes; Pier Paolo Peruzzi; Sean Lawler
Journal:  Trends Mol Med       Date:  2014-07-12       Impact factor: 11.951

Review 2.  Self-consumption: the interplay of autophagy and apoptosis.

Authors:  Guillermo Mariño; Mireia Niso-Santano; Eric H Baehrecke; Guido Kroemer
Journal:  Nat Rev Mol Cell Biol       Date:  2014-01-08       Impact factor: 94.444

Review 3.  Interleukin-6 signaling pathway in targeted therapy for cancer.

Authors:  Yuqi Guo; Feng Xu; TianJian Lu; Zhenfeng Duan; Zhan Zhang
Journal:  Cancer Treat Rev       Date:  2012-05-29       Impact factor: 12.111

Review 4.  Immunogenic cell death and DAMPs in cancer therapy.

Authors:  Dmitri V Krysko; Abhishek D Garg; Agnieszka Kaczmarek; Olga Krysko; Patrizia Agostinis; Peter Vandenabeele
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

Review 5.  Calreticulin in the immune system: ins and outs.

Authors:  Malini Raghavan; Sanjeeva J Wijeyesakere; Larry Robert Peters; Natasha Del Cid
Journal:  Trends Immunol       Date:  2012-09-07       Impact factor: 16.687

6.  Cyclic AMP modulates the functional plasticity of immature dendritic cells by inhibiting Src-like kinases through protein kinase A-mediated signaling.

Authors:  Mario Galgani; Veronica De Rosa; Salvatore De Simone; Antonio Leonardi; Ugo D'Oro; Giorgio Napolitani; Anna Maria Masci; Serafino Zappacosta; Luigi Racioppi
Journal:  J Biol Chem       Date:  2004-05-27       Impact factor: 5.157

Review 7.  Strange attractors: DAMPs and autophagy link tumor cell death and immunity.

Authors:  W Hou; Q Zhang; Z Yan; R Chen; H J Zeh Iii; R Kang; M T Lotze; D Tang
Journal:  Cell Death Dis       Date:  2013-12-12       Impact factor: 8.469

8.  Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer.

Authors:  T Colangelo; G Polcaro; P Ziccardi; B Pucci; L Muccillo; M Galgani; A Fucci; M R Milone; A Budillon; M Santopaolo; C Votino; M Pancione; A Piepoli; G Mazzoccoli; M Binaschi; M Bigioni; C A Maggi; M Fassan; C Laudanna; G Matarese; L Sabatino; V Colantuoni
Journal:  Cell Death Dis       Date:  2016-02-25       Impact factor: 8.469

Review 9.  MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer.

Authors:  Lina Cekaite; Peter W Eide; Guro E Lind; Rolf I Skotheim; Ragnhild A Lothe
Journal:  Oncotarget       Date:  2016-02-09

10.  Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.

Authors:  Abhishek D Garg; Lorenzo Galluzzi; Lionel Apetoh; Thais Baert; Raymond B Birge; José Manuel Bravo-San Pedro; Karine Breckpot; David Brough; Ricardo Chaurio; Mara Cirone; An Coosemans; Pierre G Coulie; Dirk De Ruysscher; Luciana Dini; Peter de Witte; Aleksandra M Dudek-Peric; Alberto Faggioni; Jitka Fucikova; Udo S Gaipl; Jakub Golab; Marie-Lise Gougeon; Michael R Hamblin; Akseli Hemminki; Martin Herrmann; James W Hodge; Oliver Kepp; Guido Kroemer; Dmitri V Krysko; Walter G Land; Frank Madeo; Angelo A Manfredi; Stephen R Mattarollo; Christian Maueroder; Nicolò Merendino; Gabriele Multhoff; Thomas Pabst; Jean-Ehrland Ricci; Chiara Riganti; Erminia Romano; Nicole Rufo; Mark J Smyth; Jürgen Sonnemann; Radek Spisek; John Stagg; Erika Vacchelli; Peter Vandenabeele; Lien Vandenberk; Benoit J Van den Eynde; Stefaan Van Gool; Francesca Velotti; Laurence Zitvogel; Patrizia Agostinis
Journal:  Front Immunol       Date:  2015-11-20       Impact factor: 7.561

View more
  29 in total

1.  Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression.

Authors:  Changlin Li; Hui Sun; Wei Wei; Qiuzi Liu; Yinglei Wang; Ying Zhang; Fuming Lian; Fangchao Liu; Chenchen Li; Kaicheng Ying; Hang Huo; Zhi Qi; Benyi Li
Journal:  Cell Oncol (Dordr)       Date:  2020-07-24       Impact factor: 6.730

2.  Proteomic characterization of peroxisome proliferator-activated receptor-γ (PPARγ) overexpressing or silenced colorectal cancer cells unveils a novel protein network associated with an aggressive phenotype.

Authors:  Maria Rita Milone; Biagio Pucci; Tommaso Colangelo; Rita Lombardi; Federica Iannelli; Vittorio Colantuoni; Lina Sabatino; Alfredo Budillon
Journal:  Mol Oncol       Date:  2016-07-25       Impact factor: 6.603

Review 3.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Authors:  Abhishek D Garg; Sanket More; Nicole Rufo; Odeta Mece; Maria Livia Sassano; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

4.  ZNFX1 anti-sense RNA 1 promotes the tumorigenesis of prostate cancer by regulating c-Myc expression via a regulatory network of competing endogenous RNAs.

Authors:  Xiaolu Cui; Chiyuan Piao; Chengcheng Lv; Xuyong Lin; Zhe Zhang; Xiankui Liu
Journal:  Cell Mol Life Sci       Date:  2019-07-18       Impact factor: 9.261

5.  Huaier Induces Immunogenic Cell Death Via CircCLASP1/PKR/eIF2α Signaling Pathway in Triple Negative Breast Cancer.

Authors:  Chen Li; Xiaolong Wang; Tong Chen; Wenhao Li; Xianyong Zhou; Lishui Wang; Qifeng Yang
Journal:  Front Cell Dev Biol       Date:  2022-06-16

Review 6.  A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion.

Authors:  Devin Dersh; Jaroslav Hollý; Jonathan W Yewdell
Journal:  Nat Rev Immunol       Date:  2020-08-20       Impact factor: 53.106

Review 7.  Small extracellular vesicles in cancer.

Authors:  Komal Abhange; Amy Makler; Yi Wen; Natasha Ramnauth; Wenjun Mao; Waseem Asghar; Yuan Wan
Journal:  Bioact Mater       Date:  2021-04-07

8.  Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1.

Authors:  Daniel J Klionsky; Amal Kamal Abdel-Aziz; Sara Abdelfatah; Mahmoud Abdellatif; Asghar Abdoli; Steffen Abel; Hagai Abeliovich; Marie H Abildgaard; Yakubu Princely Abudu; Abraham Acevedo-Arozena; Iannis E Adamopoulos; Khosrow Adeli; Timon E Adolph; Annagrazia Adornetto; Elma Aflaki; Galila Agam; Anupam Agarwal; Bharat B Aggarwal; Maria Agnello; Patrizia Agostinis; Javed N Agrewala; Alexander Agrotis; Patricia V Aguilar; S Tariq Ahmad; Zubair M Ahmed; Ulises Ahumada-Castro; Sonja Aits; Shu Aizawa; Yunus Akkoc; Tonia Akoumianaki; Hafize Aysin Akpinar; Ahmed M Al-Abd; Lina Al-Akra; Abeer Al-Gharaibeh; Moulay A Alaoui-Jamali; Simon Alberti; Elísabet Alcocer-Gómez; Cristiano Alessandri; Muhammad Ali; M Abdul Alim Al-Bari; Saeb Aliwaini; Javad Alizadeh; Eugènia Almacellas; Alexandru Almasan; Alicia Alonso; Guillermo D Alonso; Nihal Altan-Bonnet; Dario C Altieri; Élida M C Álvarez; Sara Alves; Cristine Alves da Costa; Mazen M Alzaharna; Marialaura Amadio; Consuelo Amantini; Cristina Amaral; Susanna Ambrosio; Amal O Amer; Veena Ammanathan; Zhenyi An; Stig U Andersen; Shaida A Andrabi; Magaiver Andrade-Silva; Allen M Andres; Sabrina Angelini; David Ann; Uche C Anozie; Mohammad Y Ansari; Pedro Antas; Adam Antebi; Zuriñe Antón; Tahira Anwar; Lionel Apetoh; Nadezda Apostolova; Toshiyuki Araki; Yasuhiro Araki; Kohei Arasaki; Wagner L Araújo; Jun Araya; Catherine Arden; Maria-Angeles Arévalo; Sandro Arguelles; Esperanza Arias; Jyothi Arikkath; Hirokazu Arimoto; Aileen R Ariosa; Darius Armstrong-James; Laetitia Arnauné-Pelloquin; Angeles Aroca; Daniela S Arroyo; Ivica Arsov; Rubén Artero; Dalia Maria Lucia Asaro; Michael Aschner; Milad Ashrafizadeh; Osnat Ashur-Fabian; Atanas G Atanasov; Alicia K Au; Patrick Auberger; Holger W Auner; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Yenniffer Ávalos; Sanja Aveic; Célia Alexandra Aveleira; Tamar Avin-Wittenberg; Yucel Aydin; Scott Ayton; Srinivas Ayyadevara; Maria Azzopardi; Misuzu Baba; Jonathan M Backer; Steven K Backues; Dong-Hun Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Ahruem Baek; Seung-Hoon Baek; Sung Hee Baek; Giacinto Bagetta; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xiyuan Bai; Yidong Bai; Nandadulal Bairagi; Shounak Baksi; Teresa Balbi; Cosima T Baldari; Walter Balduini; Andrea Ballabio; Maria Ballester; Salma Balazadeh; Rena Balzan; Rina Bandopadhyay; Sreeparna Banerjee; Sulagna Banerjee; Ágnes Bánréti; Yan Bao; Mauricio S Baptista; Alessandra Baracca; Cristiana Barbati; Ariadna Bargiela; Daniela Barilà; Peter G Barlow; Sami J Barmada; Esther Barreiro; George E Barreto; Jiri Bartek; Bonnie Bartel; Alberto Bartolome; Gaurav R Barve; Suresh H Basagoudanavar; Diane C Bassham; Robert C Bast; Alakananda Basu; Henri Batoko; Isabella Batten; Etienne E Baulieu; Bradley L Baumgarner; Jagadeesh Bayry; Rupert Beale; Isabelle Beau; Florian Beaumatin; Luiz R G Bechara; George R Beck; Michael F Beers; Jakob Begun; Christian Behrends; Georg M N Behrens; Roberto Bei; Eloy Bejarano; Shai Bel; Christian Behl; Amine Belaid; Naïma Belgareh-Touzé; Cristina Bellarosa; Francesca Belleudi; Melissa Belló Pérez; Raquel Bello-Morales; Jackeline Soares de Oliveira Beltran; Sebastián Beltran; Doris Mangiaracina Benbrook; Mykolas Bendorius; Bruno A Benitez; Irene Benito-Cuesta; Julien Bensalem; Martin W Berchtold; Sabina Berezowska; Daniele Bergamaschi; Matteo Bergami; Andreas Bergmann; Laura Berliocchi; Clarisse Berlioz-Torrent; Amélie Bernard; Lionel Berthoux; Cagri G Besirli; Sebastien Besteiro; Virginie M Betin; Rudi Beyaert; Jelena S Bezbradica; Kiran Bhaskar; Ingrid Bhatia-Kissova; Resham Bhattacharya; Sujoy Bhattacharya; Shalmoli Bhattacharyya; Md Shenuarin Bhuiyan; Sujit Kumar Bhutia; Lanrong Bi; Xiaolin Bi; Trevor J Biden; Krikor Bijian; Viktor A Billes; Nadine Binart; Claudia Bincoletto; Asa B Birgisdottir; Geir Bjorkoy; Gonzalo Blanco; Ana Blas-Garcia; Janusz Blasiak; Robert Blomgran; Klas Blomgren; Janice S Blum; Emilio Boada-Romero; Mirta Boban; Kathleen Boesze-Battaglia; Philippe Boeuf; Barry Boland; Pascale Bomont; Paolo Bonaldo; Srinivasa Reddy Bonam; Laura Bonfili; Juan S Bonifacino; Brian A Boone; Martin D Bootman; Matteo Bordi; Christoph Borner; Beat C Bornhauser; Gautam Borthakur; Jürgen Bosch; Santanu Bose; Luis M Botana; Juan Botas; Chantal M Boulanger; Michael E Boulton; Mathieu Bourdenx; Benjamin Bourgeois; Nollaig M Bourke; Guilhem Bousquet; Patricia Boya; Peter V Bozhkov; Luiz H M Bozi; Tolga O Bozkurt; Doug E Brackney; Christian H Brandts; Ralf J Braun; Gerhard H Braus; Roberto Bravo-Sagua; José M Bravo-San Pedro; Patrick Brest; Marie-Agnès Bringer; Alfredo Briones-Herrera; V Courtney Broaddus; Peter Brodersen; Jeffrey L Brodsky; Steven L Brody; Paola G Bronson; Jeff M Bronstein; Carolyn N Brown; Rhoderick E Brown; Patricia C Brum; John H Brumell; Nicola Brunetti-Pierri; Daniele Bruno; Robert J Bryson-Richardson; Cecilia Bucci; Carmen Buchrieser; Marta Bueno; Laura Elisa Buitrago-Molina; Simone Buraschi; Shilpa Buch; J Ross Buchan; Erin M Buckingham; Hikmet Budak; Mauricio Budini; Geert Bultynck; Florin Burada; Joseph R Burgoyne; M Isabel Burón; Victor Bustos; Sabrina Büttner; Elena Butturini; Aaron Byrd; Isabel Cabas; Sandra Cabrera-Benitez; Ken Cadwell; Jingjing Cai; Lu Cai; Qian Cai; Montserrat Cairó; Jose A Calbet; Guy A Caldwell; Kim A Caldwell; Jarrod A Call; Riccardo Calvani; Ana C Calvo; Miguel Calvo-Rubio Barrera; Niels Os Camara; Jacques H Camonis; Nadine Camougrand; Michelangelo Campanella; Edward M Campbell; François-Xavier Campbell-Valois; Silvia Campello; Ilaria Campesi; Juliane C Campos; Olivier Camuzard; Jorge Cancino; Danilo Candido de Almeida; Laura Canesi; Isabella Caniggia; Barbara Canonico; Carles Cantí; Bin Cao; Michele Caraglia; Beatriz Caramés; Evie H Carchman; Elena Cardenal-Muñoz; Cesar Cardenas; Luis Cardenas; Sandra M Cardoso; Jennifer S Carew; Georges F Carle; Gillian Carleton; Silvia Carloni; Didac Carmona-Gutierrez; Leticia A Carneiro; Oliana Carnevali; Julian M Carosi; Serena Carra; Alice Carrier; Lucie Carrier; Bernadette Carroll; A Brent Carter; Andreia Neves Carvalho; Magali Casanova; Caty Casas; Josefina Casas; Chiara Cassioli; Eliseo F Castillo; Karen Castillo; Sonia Castillo-Lluva; Francesca Castoldi; Marco Castori; Ariel F Castro; Margarida Castro-Caldas; Javier Castro-Hernandez; Susana Castro-Obregon; Sergio D Catz; Claudia Cavadas; Federica Cavaliere; Gabriella Cavallini; Maria Cavinato; Maria L Cayuela; Paula Cebollada Rica; Valentina Cecarini; Francesco Cecconi; Marzanna Cechowska-Pasko; Simone Cenci; Victòria Ceperuelo-Mallafré; João J Cerqueira; Janete M Cerutti; Davide Cervia; Vildan Bozok Cetintas; Silvia Cetrullo; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Oishee Chakrabarti; Tapas Chakraborty; Trinad Chakraborty; Mounia Chami; Georgios Chamilos; David W Chan; Edmond Y W Chan; Edward D Chan; H Y Edwin Chan; Helen H Chan; Hung Chan; Matthew T V Chan; Yau Sang Chan; Partha K Chandra; Chih-Peng Chang; Chunmei Chang; Hao-Chun Chang; Kai Chang; Jie Chao; Tracey Chapman; Nicolas Charlet-Berguerand; Samrat Chatterjee; Shail K Chaube; Anu Chaudhary; Santosh Chauhan; Edward Chaum; Frédéric Checler; Michael E Cheetham; Chang-Shi Chen; Guang-Chao Chen; Jian-Fu Chen; Liam L Chen; Leilei Chen; Lin Chen; Mingliang Chen; Mu-Kuan Chen; Ning Chen; Quan Chen; Ruey-Hwa Chen; Shi Chen; Wei Chen; Weiqiang Chen; Xin-Ming Chen; Xiong-Wen Chen; Xu Chen; Yan Chen; Ye-Guang Chen; Yingyu Chen; Yongqiang Chen; Yu-Jen Chen; Yue-Qin Chen; Zhefan Stephen Chen; Zhi Chen; Zhi-Hua Chen; Zhijian J Chen; Zhixiang Chen; Hanhua Cheng; Jun Cheng; Shi-Yuan Cheng; Wei Cheng; Xiaodong Cheng; Xiu-Tang Cheng; Yiyun Cheng; Zhiyong Cheng; Zhong Chen; Heesun Cheong; Jit Kong Cheong; Boris V Chernyak; Sara Cherry; Chi Fai Randy Cheung; Chun Hei Antonio Cheung; King-Ho Cheung; Eric Chevet; Richard J Chi; Alan Kwok Shing Chiang; Ferdinando Chiaradonna; Roberto Chiarelli; Mario Chiariello; Nathalia Chica; Susanna Chiocca; Mario Chiong; Shih-Hwa Chiou; Abhilash I Chiramel; Valerio Chiurchiù; Dong-Hyung Cho; Seong-Kyu Choe; Augustine M K Choi; Mary E Choi; Kamalika Roy Choudhury; Norman S Chow; Charleen T Chu; Jason P Chua; John Jia En Chua; Hyewon Chung; Kin Pan Chung; Seockhoon Chung; So-Hyang Chung; Yuen-Li Chung; Valentina Cianfanelli; Iwona A Ciechomska; Mariana Cifuentes; Laura Cinque; Sebahattin Cirak; Mara Cirone; Michael J Clague; Robert Clarke; Emilio Clementi; Eliana M Coccia; Patrice Codogno; Ehud Cohen; Mickael M Cohen; Tania Colasanti; Fiorella Colasuonno; Robert A Colbert; Anna Colell; Miodrag Čolić; Nuria S Coll; Mark O Collins; María I Colombo; Daniel A Colón-Ramos; Lydie Combaret; Sergio Comincini; Márcia R Cominetti; Antonella Consiglio; Andrea Conte; Fabrizio Conti; Viorica Raluca Contu; Mark R Cookson; Kevin M Coombs; Isabelle Coppens; Maria Tiziana Corasaniti; Dale P Corkery; Nils Cordes; Katia Cortese; Maria do Carmo Costa; Sarah Costantino; Paola Costelli; Ana Coto-Montes; Peter J Crack; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Riccardo Cristofani; Tamas Csizmadia; Antonio Cuadrado; Bing Cui; Jun Cui; Yixian Cui; Yong Cui; Emmanuel Culetto; Andrea C Cumino; Andrey V Cybulsky; Mark J Czaja; Stanislaw J Czuczwar; Stefania D'Adamo; Marcello D'Amelio; Daniela D'Arcangelo; Andrew C D'Lugos; Gabriella D'Orazi; James A da Silva; Hormos Salimi Dafsari; Ruben K Dagda; Yasin Dagdas; Maria Daglia; Xiaoxia Dai; Yun Dai; Yuyuan Dai; Jessica Dal Col; Paul Dalhaimer; Luisa Dalla Valle; Tobias Dallenga; Guillaume Dalmasso; Markus Damme; Ilaria Dando; Nico P Dantuma; April L Darling; Hiranmoy Das; Srinivasan Dasarathy; Santosh K Dasari; Srikanta Dash; Oliver Daumke; Adrian N Dauphinee; Jeffrey S Davies; Valeria A Dávila; Roger J Davis; Tanja Davis; Sharadha Dayalan Naidu; Francesca De Amicis; Karolien De Bosscher; Francesca De Felice; Lucia De Franceschi; Chiara De Leonibus; Mayara G de Mattos Barbosa; Guido R Y De Meyer; Angelo De Milito; Cosimo De Nunzio; Clara De Palma; Mauro De Santi; Claudio De Virgilio; Daniela De Zio; Jayanta Debnath; Brian J DeBosch; Jean-Paul Decuypere; Mark A Deehan; Gianluca Deflorian; James DeGregori; Benjamin Dehay; Gabriel Del Rio; Joe R Delaney; Lea M D Delbridge; Elizabeth Delorme-Axford; M Victoria Delpino; Francesca Demarchi; Vilma Dembitz; Nicholas D Demers; Hongbin Deng; Zhiqiang Deng; Joern Dengjel; Paul Dent; Donna Denton; Melvin L DePamphilis; Channing J Der; Vojo Deretic; Albert Descoteaux; Laura Devis; Sushil Devkota; Olivier Devuyst; Grant Dewson; Mahendiran Dharmasivam; Rohan Dhiman; Diego di Bernardo; Manlio Di Cristina; Fabio Di Domenico; Pietro Di Fazio; Alessio Di Fonzo; Giovanni Di Guardo; Gianni M Di Guglielmo; Luca Di Leo; Chiara Di Malta; Alessia Di Nardo; Martina Di Rienzo; Federica Di Sano; George Diallinas; Jiajie Diao; Guillermo Diaz-Araya; Inés Díaz-Laviada; Jared M Dickinson; Marc Diederich; Mélanie Dieudé; Ivan Dikic; Shiping Ding; Wen-Xing Ding; Luciana Dini; Jelena Dinić; Miroslav Dinic; Albena T Dinkova-Kostova; Marc S Dionne; Jörg H W Distler; Abhinav Diwan; Ian M C Dixon; Mojgan Djavaheri-Mergny; Ina Dobrinski; Oxana Dobrovinskaya; Radek Dobrowolski; Renwick C J Dobson; Jelena Đokić; Serap Dokmeci Emre; Massimo Donadelli; Bo Dong; Xiaonan Dong; Zhiwu Dong; Gerald W Dorn Ii; Volker Dotsch; Huan Dou; Juan Dou; Moataz Dowaidar; Sami Dridi; Liat Drucker; Ailian Du; Caigan Du; Guangwei Du; Hai-Ning Du; Li-Lin Du; André du Toit; Shao-Bin Duan; Xiaoqiong Duan; Sónia P Duarte; Anna Dubrovska; Elaine A Dunlop; Nicolas Dupont; Raúl V Durán; Bilikere S Dwarakanath; Sergey A Dyshlovoy; Darius Ebrahimi-Fakhari; Leopold Eckhart; Charles L Edelstein; Thomas Efferth; Eftekhar Eftekharpour; Ludwig Eichinger; Nabil Eid; Tobias Eisenberg; N Tony Eissa; Sanaa Eissa; Miriam Ejarque; Abdeljabar El Andaloussi; Nazira El-Hage; Shahenda El-Naggar; Anna Maria Eleuteri; Eman S El-Shafey; Mohamed Elgendy; Aristides G Eliopoulos; María M Elizalde; Philip M Elks; Hans-Peter Elsasser; Eslam S Elsherbiny; Brooke M Emerling; N C Tolga Emre; Christina H Eng; Nikolai Engedal; Anna-Mart Engelbrecht; Agnete S T Engelsen; Jorrit M Enserink; Ricardo Escalante; Audrey Esclatine; Mafalda Escobar-Henriques; Eeva-Liisa Eskelinen; Lucile Espert; Makandjou-Ola Eusebio; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Francesco Facchiano; Bengt Fadeel; Claudio Fader; Alex C Faesen; W Douglas Fairlie; Alberto Falcó; Bjorn H Falkenburger; Daping Fan; Jie Fan; Yanbo Fan; Evandro F Fang; Yanshan Fang; Yognqi Fang; Manolis Fanto; Tamar Farfel-Becker; Mathias Faure; Gholamreza Fazeli; Anthony O Fedele; Arthur M Feldman; Du Feng; Jiachun Feng; Lifeng Feng; Yibin Feng; Yuchen Feng; Wei Feng; Thais Fenz Araujo; Thomas A Ferguson; Álvaro F Fernández; Jose C Fernandez-Checa; Sonia Fernández-Veledo; Alisdair R Fernie; Anthony W Ferrante; Alessandra Ferraresi; Merari F Ferrari; Julio C B Ferreira; Susan Ferro-Novick; Antonio Figueras; Riccardo Filadi; Nicoletta Filigheddu; Eduardo Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; Vittorio Fineschi; Francesca Finetti; Steven Finkbeiner; Edward A Fisher; Paul B Fisher; Flavio Flamigni; Steven J Fliesler; Trude H Flo; Ida Florance; Oliver Florey; Tullio Florio; Erika Fodor; Carlo Follo; Edward A Fon; Antonella Forlino; Francesco Fornai; Paola Fortini; Anna Fracassi; Alessandro Fraldi; Brunella Franco; Rodrigo Franco; Flavia Franconi; Lisa B Frankel; Scott L Friedman; Leopold F Fröhlich; Gema Frühbeck; Jose M Fuentes; Yukio Fujiki; Naonobu Fujita; Yuuki Fujiwara; Mitsunori Fukuda; Simone Fulda; Luc Furic; Norihiko Furuya; Carmela Fusco; Michaela U Gack; Lidia Gaffke; Sehamuddin Galadari; Alessia Galasso; Maria F Galindo; Sachith Gallolu Kankanamalage; Lorenzo Galluzzi; Vincent Galy; Noor Gammoh; Boyi Gan; Ian G Ganley; Feng Gao; Hui Gao; Minghui Gao; Ping Gao; Shou-Jiang Gao; Wentao Gao; Xiaobo Gao; Ana Garcera; Maria Noé Garcia; Verónica E Garcia; Francisco García-Del Portillo; Vega Garcia-Escudero; Aracely Garcia-Garcia; Marina Garcia-Macia; Diana García-Moreno; Carmen Garcia-Ruiz; Patricia García-Sanz; Abhishek D Garg; Ricardo Gargini; Tina Garofalo; Robert F Garry; Nils C Gassen; Damian Gatica; Liang Ge; Wanzhong Ge; Ruth Geiss-Friedlander; Cecilia Gelfi; Pascal Genschik; Ian E Gentle; Valeria Gerbino; Christoph Gerhardt; Kyla Germain; Marc Germain; David A Gewirtz; Elham Ghasemipour Afshar; Saeid Ghavami; Alessandra Ghigo; Manosij Ghosh; Georgios Giamas; Claudia Giampietri; Alexandra Giatromanolaki; Gary E Gibson; Spencer B Gibson; Vanessa Ginet; Edward Giniger; Carlotta Giorgi; Henrique Girao; Stephen E Girardin; Mridhula Giridharan; Sandy Giuliano; Cecilia Giulivi; Sylvie Giuriato; Julien Giustiniani; Alexander Gluschko; Veit Goder; Alexander Goginashvili; Jakub Golab; David C Goldstone; Anna Golebiewska; Luciana R Gomes; Rodrigo Gomez; Rubén Gómez-Sánchez; Maria Catalina Gomez-Puerto; Raquel Gomez-Sintes; Qingqiu Gong; Felix M Goni; Javier González-Gallego; Tomas Gonzalez-Hernandez; Rosa A Gonzalez-Polo; Jose A Gonzalez-Reyes; Patricia González-Rodríguez; Ing Swie Goping; Marina S Gorbatyuk; Nikolai V Gorbunov; Kıvanç Görgülü; Roxana M Gorojod; Sharon M Gorski; Sandro Goruppi; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Martin Graef; Markus H Gräler; Veronica Granatiero; Daniel Grasso; Joshua P Gray; Douglas R Green; Alexander Greenhough; Stephen L Gregory; Edward F Griffin; Mark W Grinstaff; Frederic Gros; Charles Grose; Angelina S Gross; Florian Gruber; Paolo Grumati; Tilman Grune; Xueyan Gu; Jun-Lin Guan; Carlos M Guardia; Kishore Guda; Flora Guerra; Consuelo Guerri; Prasun Guha; Carlos Guillén; Shashi Gujar; Anna Gukovskaya; Ilya Gukovsky; Jan Gunst; Andreas Günther; Anyonya R Guntur; Chuanyong Guo; Chun Guo; Hongqing Guo; Lian-Wang Guo; Ming Guo; Pawan Gupta; Shashi Kumar Gupta; Swapnil Gupta; Veer Bala Gupta; Vivek Gupta; Asa B Gustafsson; David D Gutterman; Ranjitha H B; Annakaisa Haapasalo; James E Haber; Aleksandra Hać; Shinji Hadano; Anders J Hafrén; Mansour Haidar; Belinda S Hall; Gunnel Halldén; Anne Hamacher-Brady; Andrea Hamann; Maho Hamasaki; Weidong Han; Malene Hansen; Phyllis I Hanson; Zijian Hao; Masaru Harada; Ljubica Harhaji-Trajkovic; Nirmala Hariharan; Nigil Haroon; James Harris; Takafumi Hasegawa; Noor Hasima Nagoor; Jeffrey A Haspel; Volker Haucke; Wayne D Hawkins; Bruce A Hay; Cole M Haynes; Soren B Hayrabedyan; Thomas S Hays; Congcong He; Qin He; Rong-Rong He; You-Wen He; Yu-Ying He; Yasser Heakal; Alexander M Heberle; J Fielding Hejtmancik; Gudmundur Vignir Helgason; Vanessa Henkel; Marc Herb; Alexander Hergovich; Anna Herman-Antosiewicz; Agustín Hernández; Carlos Hernandez; Sergio Hernandez-Diaz; Virginia Hernandez-Gea; Amaury Herpin; Judit Herreros; Javier H Hervás; Daniel Hesselson; Claudio Hetz; Volker T Heussler; Yujiro Higuchi; Sabine Hilfiker; Joseph A Hill; William S Hlavacek; Emmanuel A Ho; Idy H T Ho; Philip Wing-Lok Ho; Shu-Leong Ho; Wan Yun Ho; G Aaron Hobbs; Mark Hochstrasser; Peter H M Hoet; Daniel Hofius; Paul Hofman; Annika Höhn; Carina I Holmberg; Jose R Hombrebueno; Chang-Won Hong Yi-Ren Hong; Lora V Hooper; Thorsten Hoppe; Rastislav Horos; Yujin Hoshida; I-Lun Hsin; Hsin-Yun Hsu; Bing Hu; Dong Hu; Li-Fang Hu; Ming Chang Hu; Ronggui Hu; Wei Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Jinlian Hua; Yingqi Hua; Chongmin Huan; Canhua Huang; Chuanshu Huang; Chuanxin Huang; Chunling Huang; Haishan Huang; Kun Huang; Michael L H Huang; Rui Huang; Shan Huang; Tianzhi Huang; Xing Huang; Yuxiang Jack Huang; Tobias B Huber; Virginie Hubert; Christian A Hubner; Stephanie M Hughes; William E Hughes; Magali Humbert; Gerhard Hummer; James H Hurley; Sabah Hussain; Salik Hussain; Patrick J Hussey; Martina Hutabarat; Hui-Yun Hwang; Seungmin Hwang; Antonio Ieni; Fumiyo Ikeda; Yusuke Imagawa; Yuzuru Imai; Carol Imbriano; Masaya Imoto; Denise M Inman; Ken Inoki; Juan Iovanna; Renato V Iozzo; Giuseppe Ippolito; Javier E Irazoqui; Pablo Iribarren; Mohd Ishaq; Makoto Ishikawa; Nestor Ishimwe; Ciro Isidoro; Nahed Ismail; Shohreh Issazadeh-Navikas; Eisuke Itakura; Daisuke Ito; Davor Ivankovic; Saška Ivanova; Anand Krishnan V Iyer; José M Izquierdo; Masanori Izumi; Marja Jäättelä; Majid Sakhi Jabir; William T Jackson; Nadia Jacobo-Herrera; Anne-Claire Jacomin; Elise Jacquin; Pooja Jadiya; Hartmut Jaeschke; Chinnaswamy Jagannath; Arjen J Jakobi; Johan Jakobsson; Bassam Janji; Pidder Jansen-Dürr; Patric J Jansson; Jonathan Jantsch; Sławomir Januszewski; Alagie Jassey; Steve Jean; Hélène Jeltsch-David; Pavla Jendelova; Andreas Jenny; Thomas E Jensen; Niels Jessen; Jenna L Jewell; Jing Ji; Lijun Jia; Rui Jia; Liwen Jiang; Qing Jiang; Richeng Jiang; Teng Jiang; Xuejun Jiang; Yu Jiang; Maria Jimenez-Sanchez; Eun-Jung Jin; Fengyan Jin; Hongchuan Jin; Li Jin; Luqi Jin; Meiyan Jin; Si Jin; Eun-Kyeong Jo; Carine Joffre; Terje Johansen; Gail V W Johnson; Simon A Johnston; Eija Jokitalo; Mohit Kumar Jolly; Leo A B Joosten; Joaquin Jordan; Bertrand Joseph; Dianwen Ju; Jeong-Sun Ju; Jingfang Ju; Esmeralda Juárez; Delphine Judith; Gábor Juhász; Youngsoo Jun; Chang Hwa Jung; Sung-Chul Jung; Yong Keun Jung; Heinz Jungbluth; Johannes Jungverdorben; Steffen Just; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Daniel Kaganovich; Alon Kahana; Renate Kain; Shinjo Kajimura; Maria Kalamvoki; Manjula Kalia; Danuta S Kalinowski; Nina Kaludercic; Ioanna Kalvari; Joanna Kaminska; Vitaliy O Kaminskyy; Hiromitsu Kanamori; Keizo Kanasaki; Chanhee Kang; Rui Kang; Sang Sun Kang; Senthilvelrajan Kaniyappan; Tomotake Kanki; Thirumala-Devi Kanneganti; Anumantha G Kanthasamy; Arthi Kanthasamy; Marc Kantorow; Orsolya Kapuy; Michalis V Karamouzis; Md Razaul Karim; Parimal Karmakar; Rajesh G Katare; Masaru Kato; Stefan H E Kaufmann; Anu Kauppinen; Gur P Kaushal; Susmita Kaushik; Kiyoshi Kawasaki; Kemal Kazan; Po-Yuan Ke; Damien J Keating; Ursula Keber; John H Kehrl; Kate E Keller; Christian W Keller; Jongsook Kim Kemper; Candia M Kenific; Oliver Kepp; Stephanie Kermorgant; Andreas Kern; Robin Ketteler; Tom G Keulers; Boris Khalfin; Hany Khalil; Bilon Khambu; Shahid Y Khan; Vinoth Kumar Megraj Khandelwal; Rekha Khandia; Widuri Kho; Noopur V Khobrekar; Sataree Khuansuwan; Mukhran Khundadze; Samuel A Killackey; Dasol Kim; Deok Ryong Kim; Do-Hyung Kim; Dong-Eun Kim; Eun Young Kim; Eun-Kyoung Kim; Hak-Rim Kim; Hee-Sik Kim; Jeong Hun Kim; Jin Kyung Kim; Jin-Hoi Kim; Joungmok Kim; Ju Hwan Kim; Keun Il Kim; Peter K Kim; Seong-Jun Kim; Scot R Kimball; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Matthew A King; Kerri J Kinghorn; Conan G Kinsey; Vladimir Kirkin; Lorrie A Kirshenbaum; Sergey L Kiselev; Shuji Kishi; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Richard N Kitsis; Josef T Kittler; Ole Kjaerulff; Peter S Klein; Thomas Klopstock; Jochen Klucken; Helene Knævelsrud; Roland L Knorr; Ben C B Ko; Fred Ko; Jiunn-Liang Ko; Hotaka Kobayashi; Satoru Kobayashi; Ina Koch; Jan C Koch; Ulrich Koenig; Donat Kögel; Young Ho Koh; Masato Koike; Sepp D Kohlwein; Nur M Kocaturk; Masaaki Komatsu; Jeannette König; Toru Kono; Benjamin T Kopp; Tamas Korcsmaros; Gözde Korkmaz; Viktor I Korolchuk; Mónica Suárez Korsnes; Ali Koskela; Janaiah Kota; Yaichiro Kotake; Monica L Kotler; Yanjun Kou; Michael I Koukourakis; Evangelos Koustas; Attila L Kovacs; Tibor Kovács; Daisuke Koya; Tomohiro Kozako; Claudine Kraft; Dimitri Krainc; Helmut Krämer; Anna D Krasnodembskaya; Carole Kretz-Remy; Guido Kroemer; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Sabine Kuenen; Lars Kuerschner; Thomas Kukar; Ajay Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Sharad Kumar; Shinji Kume; Caroline Kumsta; Chanakya N Kundu; Mondira Kundu; Ajaikumar B Kunnumakkara; Lukasz Kurgan; Tatiana G Kutateladze; Ozlem Kutlu; SeongAe Kwak; Ho Jeong Kwon; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert La Spada; Patrick Labonté; Sylvain Ladoire; Ilaria Laface; Frank Lafont; Diane C Lagace; Vikramjit Lahiri; Zhibing Lai; Angela S Laird; Aparna Lakkaraju; Trond Lamark; Sheng-Hui Lan; Ane Landajuela; Darius J R Lane; Jon D Lane; Charles H Lang; Carsten Lange; Ülo Langel; Rupert Langer; Pierre Lapaquette; Jocelyn Laporte; Nicholas F LaRusso; Isabel Lastres-Becker; Wilson Chun Yu Lau; Gordon W Laurie; Sergio Lavandero; Betty Yuen Kwan Law; Helen Ka-Wai Law; Rob Layfield; Weidong Le; Herve Le Stunff; Alexandre Y Leary; Jean-Jacques Lebrun; Lionel Y W Leck; Jean-Philippe Leduc-Gaudet; Changwook Lee; Chung-Pei Lee; Da-Hye Lee; Edward B Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Heung Kyu Lee; Jae Man Lee; Jason S Lee; Jin-A Lee; Joo-Yong Lee; Jun Hee Lee; Michael Lee; Min Goo Lee; Min Jae Lee; Myung-Shik Lee; Sang Yoon Lee; Seung-Jae Lee; Stella Y Lee; Sung Bae Lee; Won Hee Lee; Ying-Ray Lee; Yong-Ho Lee; Youngil Lee; Christophe Lefebvre; Renaud Legouis; Yu L Lei; Yuchen Lei; Sergey Leikin; Gerd Leitinger; Leticia Lemus; Shuilong Leng; Olivia Lenoir; Guido Lenz; Heinz Josef Lenz; Paola Lenzi; Yolanda León; Andréia M Leopoldino; Christoph Leschczyk; Stina Leskelä; Elisabeth Letellier; Chi-Ting Leung; Po Sing Leung; Jeremy S Leventhal; Beth Levine; Patrick A Lewis; Klaus Ley; Bin Li; Da-Qiang Li; Jianming Li; Jing Li; Jiong Li; Ke Li; Liwu Li; Mei Li; Min Li; Min Li; Ming Li; Mingchuan Li; Pin-Lan Li; Ming-Qing Li; Qing Li; Sheng Li; Tiangang Li; Wei Li; Wenming Li; Xue Li; Yi-Ping Li; Yuan Li; Zhiqiang Li; Zhiyong Li; Zhiyuan Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Weicheng Liang; Yongheng Liang; YongTian Liang; Guanghong Liao; Lujian Liao; Mingzhi Liao; Yung-Feng Liao; Mariangela Librizzi; Pearl P Y Lie; Mary A Lilly; Hyunjung J Lim; Thania R R Lima; Federica Limana; Chao Lin; Chih-Wen Lin; Dar-Shong Lin; Fu-Cheng Lin; Jiandie D Lin; Kurt M Lin; Kwang-Huei Lin; Liang-Tzung Lin; Pei-Hui Lin; Qiong Lin; Shaofeng Lin; Su-Ju Lin; Wenyu Lin; Xueying Lin; Yao-Xin Lin; Yee-Shin Lin; Rafael Linden; Paula Lindner; Shuo-Chien Ling; Paul Lingor; Amelia K Linnemann; Yih-Cherng Liou; Marta M Lipinski; Saška Lipovšek; Vitor A Lira; Natalia Lisiak; Paloma B Liton; Chao Liu; Ching-Hsuan Liu; Chun-Feng Liu; Cui Hua Liu; Fang Liu; Hao Liu; Hsiao-Sheng Liu; Hua-Feng Liu; Huifang Liu; Jia Liu; Jing Liu; Julia Liu; Leyuan Liu; Longhua Liu; Meilian Liu; Qin Liu; Wei Liu; Wende Liu; Xiao-Hong Liu; Xiaodong Liu; Xingguo Liu; Xu Liu; Xuedong Liu; Yanfen Liu; Yang Liu; Yang Liu; Yueyang Liu; Yule Liu; J Andrew Livingston; Gerard Lizard; Jose M Lizcano; Senka Ljubojevic-Holzer; Matilde E LLeonart; David Llobet-Navàs; Alicia Llorente; Chih Hung Lo; Damián Lobato-Márquez; Qi Long; Yun Chau Long; Ben Loos; Julia A Loos; Manuela G López; Guillermo López-Doménech; José Antonio López-Guerrero; Ana T López-Jiménez; Óscar López-Pérez; Israel López-Valero; Magdalena J Lorenowicz; Mar Lorente; Peter Lorincz; Laura Lossi; Sophie Lotersztajn; Penny E Lovat; Jonathan F Lovell; Alenka Lovy; Péter Lőw; Guang Lu; Haocheng Lu; Jia-Hong Lu; Jin-Jian Lu; Mengji Lu; Shuyan Lu; Alessandro Luciani; John M Lucocq; Paula Ludovico; Micah A Luftig; Morten Luhr; Diego Luis-Ravelo; Julian J Lum; Liany Luna-Dulcey; Anders H Lund; Viktor K Lund; Jan D Lünemann; Patrick Lüningschrör; Honglin Luo; Rongcan Luo; Shouqing Luo; Zhi Luo; Claudio Luparello; Bernhard Lüscher; Luan Luu; Alex Lyakhovich; Konstantin G Lyamzaev; Alf Håkon Lystad; Lyubomyr Lytvynchuk; Alvin C Ma; Changle Ma; Mengxiao Ma; Ning-Fang Ma; Quan-Hong Ma; Xinliang Ma; Yueyun Ma; Zhenyi Ma; Ormond A MacDougald; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; Sandra Maday; Frank Madeo; Muniswamy Madesh; Tobias Madl; Julio Madrigal-Matute; Akiko Maeda; Yasuhiro Maejima; Marta Magarinos; Poornima Mahavadi; Emiliano Maiani; Kenneth Maiese; Panchanan Maiti; Maria Chiara Maiuri; Barbara Majello; Michael B Major; Elena Makareeva; Fayaz Malik; Karthik Mallilankaraman; Walter Malorni; Alina Maloyan; Najiba Mammadova; Gene Chi Wai Man; Federico Manai; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Masoud H Manjili; Ravi Manjithaya; Patricio Manque; Bella B Manshian; Raquel Manzano; Claudia Manzoni; Kai Mao; Cinzia Marchese; Sandrine Marchetti; Anna Maria Marconi; Fabrizio Marcucci; Stefania Mardente; Olga A Mareninova; Marta Margeta; Muriel Mari; Sara Marinelli; Oliviero Marinelli; Guillermo Mariño; Sofia Mariotto; Richard S Marshall; Mark R Marten; Sascha Martens; Alexandre P J Martin; Katie R Martin; Sara Martin; Shaun Martin; Adrián Martín-Segura; Miguel A Martín-Acebes; Inmaculada Martin-Burriel; Marcos Martin-Rincon; Paloma Martin-Sanz; José A Martina; Wim Martinet; Aitor Martinez; Ana Martinez; Jennifer Martinez; Moises Martinez Velazquez; Nuria Martinez-Lopez; Marta Martinez-Vicente; Daniel O Martins; Joilson O Martins; Waleska K Martins; Tania Martins-Marques; Emanuele Marzetti; Shashank Masaldan; Celine Masclaux-Daubresse; Douglas G Mashek; Valentina Massa; Lourdes Massieu; Glenn R Masson; Laura Masuelli; Anatoliy I Masyuk; Tetyana V Masyuk; Paola Matarrese; Ander Matheu; Satoaki Matoba; Sachiko Matsuzaki; Pamela Mattar; Alessandro Matte; Domenico Mattoscio; José L Mauriz; Mario Mauthe; Caroline Mauvezin; Emanual Maverakis; Paola Maycotte; Johanna Mayer; Gianluigi Mazzoccoli; Cristina Mazzoni; Joseph R Mazzulli; Nami McCarty; Christine McDonald; Mitchell R McGill; Sharon L McKenna; BethAnn McLaughlin; Fionn McLoughlin; Mark A McNiven; Thomas G McWilliams; Fatima Mechta-Grigoriou; Tania Catarina Medeiros; Diego L Medina; Lynn A Megeney; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Alfred J Meijer; Annemarie H Meijer; Jakob Mejlvang; Alicia Meléndez; Annette Melk; Gonen Memisoglu; Alexandrina F Mendes; Delong Meng; Fei Meng; Tian Meng; Rubem Menna-Barreto; Manoj B Menon; Carol Mercer; Anne E Mercier; Jean-Louis Mergny; Adalberto Merighi; Seth D Merkley; Giuseppe Merla; Volker Meske; Ana Cecilia Mestre; Shree Padma Metur; Christian Meyer; Hemmo Meyer; Wenyi Mi; Jeanne Mialet-Perez; Junying Miao; Lucia Micale; Yasuo Miki; Enrico Milan; Małgorzata Milczarek; Dana L Miller; Samuel I Miller; Silke Miller; Steven W Millward; Ira Milosevic; Elena A Minina; Hamed Mirzaei; Hamid Reza Mirzaei; Mehdi Mirzaei; Amit Mishra; Nandita Mishra; Paras Kumar Mishra; Maja Misirkic Marjanovic; Roberta Misasi; Amit Misra; Gabriella Misso; Claire Mitchell; Geraldine Mitou; Tetsuji Miura; Shigeki Miyamoto; Makoto Miyazaki; Mitsunori Miyazaki; Taiga Miyazaki; Keisuke Miyazawa; Noboru Mizushima; Trine H Mogensen; Baharia Mograbi; Reza Mohammadinejad; Yasir Mohamud; Abhishek Mohanty; Sipra Mohapatra; Torsten Möhlmann; Asif Mohmmed; Anna Moles; Kelle H Moley; Maurizio Molinari; Vincenzo Mollace; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Costanza Montagna; Mervyn J Monteiro; Andrea Montella; L Ruth Montes; Barbara Montico; Vinod K Mony; Giacomo Monzio Compagnoni; Michael N Moore; Mohammad A Moosavi; Ana L Mora; Marina Mora; David Morales-Alamo; Rosario Moratalla; Paula I Moreira; Elena Morelli; Sandra Moreno; Daniel Moreno-Blas; Viviana Moresi; Benjamin Morga; Alwena H Morgan; Fabrice Morin; Hideaki Morishita; Orson L Moritz; Mariko Moriyama; Yuji Moriyasu; Manuela Morleo; Eugenia Morselli; Jose F Moruno-Manchon; Jorge Moscat; Serge Mostowy; Elisa Motori; Andrea Felinto Moura; Naima Moustaid-Moussa; Maria Mrakovcic; Gabriel Muciño-Hernández; Anupam Mukherjee; Subhadip Mukhopadhyay; Jean M Mulcahy Levy; Victoriano Mulero; Sylviane Muller; Christian Münch; Ashok Munjal; Pura Munoz-Canoves; Teresa Muñoz-Galdeano; Christian Münz; Tomokazu Murakawa; Claudia Muratori; Brona M Murphy; J Patrick Murphy; Aditya Murthy; Timo T Myöhänen; Indira U Mysorekar; Jennifer Mytych; Seyed Mohammad Nabavi; Massimo Nabissi; Péter Nagy; Jihoon Nah; Aimable Nahimana; Ichiro Nakagawa; Ken Nakamura; Hitoshi Nakatogawa; Shyam S Nandi; Meera Nanjundan; Monica Nanni; Gennaro Napolitano; Roberta Nardacci; Masashi Narita; Melissa Nassif; Ilana Nathan; Manabu Natsumeda; Ryno J Naude; Christin Naumann; Olaia Naveiras; Fatemeh Navid; Steffan T Nawrocki; Taras Y Nazarko; Francesca Nazio; Florentina Negoita; Thomas Neill; Amanda L Neisch; Luca M Neri; Mihai G Netea; Patrick Neubert; Thomas P Neufeld; Dietbert Neumann; Albert Neutzner; Phillip T Newton; Paul A Ney; Ioannis P Nezis; Charlene C W Ng; Tzi Bun Ng; Hang T T Nguyen; Long T Nguyen; Hong-Min Ni; Clíona Ní Cheallaigh; Zhenhong Ni; M Celeste Nicolao; Francesco Nicoli; Manuel Nieto-Diaz; Per Nilsson; Shunbin Ning; Rituraj Niranjan; Hiroshi Nishimune; Mireia Niso-Santano; Ralph A Nixon; Annalisa Nobili; Clevio Nobrega; Takeshi Noda; Uxía Nogueira-Recalde; Trevor M Nolan; Ivan Nombela; Ivana Novak; Beatriz Novoa; Takashi Nozawa; Nobuyuki Nukina; Carmen Nussbaum-Krammer; Jesper Nylandsted; Tracey R O'Donovan; Seónadh M O'Leary; Eyleen J O'Rourke; Mary P O'Sullivan; Timothy E O'Sullivan; Salvatore Oddo; Ina Oehme; Michinaga Ogawa; Eric Ogier-Denis; Margret H Ogmundsdottir; Besim Ogretmen; Goo Taeg Oh; Seon-Hee Oh; Young J Oh; Takashi Ohama; Yohei Ohashi; Masaki Ohmuraya; Vasileios Oikonomou; Rani Ojha; Koji Okamoto; Hitoshi Okazawa; Masahide Oku; Sara Oliván; Jorge M A Oliveira; Michael Ollmann; James A Olzmann; Shakib Omari; M Bishr Omary; Gizem Önal; Martin Ondrej; Sang-Bing Ong; Sang-Ging Ong; Anna Onnis; Juan A Orellana; Sara Orellana-Muñoz; Maria Del Mar Ortega-Villaizan; Xilma R Ortiz-Gonzalez; Elena Ortona; Heinz D Osiewacz; Abdel-Hamid K Osman; Rosario Osta; Marisa S Otegui; Kinya Otsu; Christiane Ott; Luisa Ottobrini; Jing-Hsiung James Ou; Tiago F Outeiro; Inger Oynebraten; Melek Ozturk; Gilles Pagès; Susanta Pahari; Marta Pajares; Utpal B Pajvani; Rituraj Pal; Simona Paladino; Nicolas Pallet; Michela Palmieri; Giuseppe Palmisano; Camilla Palumbo; Francesco Pampaloni; Lifeng Pan; Qingjun Pan; Wenliang Pan; Xin Pan; Ganna Panasyuk; Rahul Pandey; Udai B Pandey; Vrajesh Pandya; Francesco Paneni; Shirley Y Pang; Elisa Panzarini; Daniela L Papademetrio; Elena Papaleo; Daniel Papinski; Diana Papp; Eun Chan Park; Hwan Tae Park; Ji-Man Park; Jong-In Park; Joon Tae Park; Junsoo Park; Sang Chul Park; Sang-Youel Park; Abraham H Parola; Jan B Parys; Adrien Pasquier; Benoit Pasquier; João F Passos; Nunzia Pastore; Hemal H Patel; Daniel Patschan; Sophie Pattingre; Gustavo Pedraza-Alva; Jose Pedraza-Chaverri; Zully Pedrozo; Gang Pei; Jianming Pei; Hadas Peled-Zehavi; Joaquín M Pellegrini; Joffrey Pelletier; Miguel A Peñalva; Di Peng; Ying Peng; Fabio Penna; Maria Pennuto; Francesca Pentimalli; Cláudia Mf Pereira; Gustavo J S Pereira; Lilian C Pereira; Luis Pereira de Almeida; Nirma D Perera; Ángel Pérez-Lara; Ana B Perez-Oliva; María Esther Pérez-Pérez; Palsamy Periyasamy; Andras Perl; Cristiana Perrotta; Ida Perrotta; Richard G Pestell; Morten Petersen; Irina Petrache; Goran Petrovski; Thorsten Pfirrmann; Astrid S Pfister; Jennifer A Philips; Huifeng Pi; Anna Picca; Alicia M Pickrell; Sandy Picot; Giovanna M Pierantoni; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Karolina Pierzynowska; Federico Pietrocola; Miroslawa Pietruczuk; Claudio Pignata; Felipe X Pimentel-Muiños; Mario Pinar; Roberta O Pinheiro; Ronit Pinkas-Kramarski; Paolo Pinton; Karolina Pircs; Sujan Piya; Paola Pizzo; Theo S Plantinga; Harald W Platta; Ainhoa Plaza-Zabala; Markus Plomann; Egor Y Plotnikov; Helene Plun-Favreau; Ryszard Pluta; Roger Pocock; Stefanie Pöggeler; Christian Pohl; Marc Poirot; Angelo Poletti; Marisa Ponpuak; Hana Popelka; Blagovesta Popova; Helena Porta; Soledad Porte Alcon; Eliana Portilla-Fernandez; Martin Post; Malia B Potts; Joanna Poulton; Ted Powers; Veena Prahlad; Tomasz K Prajsnar; Domenico Praticò; Rosaria Prencipe; Muriel Priault; Tassula Proikas-Cezanne; Vasilis J Promponas; Christopher G Proud; Rosa Puertollano; Luigi Puglielli; Thomas Pulinilkunnil; Deepika Puri; Rajat Puri; Julien Puyal; Xiaopeng Qi; Yongmei Qi; Wenbin Qian; Lei Qiang; Yu Qiu; Joe Quadrilatero; Jorge Quarleri; Nina Raben; Hannah Rabinowich; Debora Ragona; Michael J Ragusa; Nader Rahimi; Marveh Rahmati; Valeria Raia; Nuno Raimundo; Namakkal-Soorappan Rajasekaran; Sriganesh Ramachandra Rao; Abdelhaq Rami; Ignacio Ramírez-Pardo; David B Ramsden; Felix Randow; Pundi N Rangarajan; Danilo Ranieri; Hai Rao; Lang Rao; Rekha Rao; Sumit Rathore; J Arjuna Ratnayaka; Edward A Ratovitski; Palaniyandi Ravanan; Gloria Ravegnini; Swapan K Ray; Babak Razani; Vito Rebecca; Fulvio Reggiori; Anne Régnier-Vigouroux; Andreas S Reichert; David Reigada; Jan H Reiling; Theo Rein; Siegfried Reipert; Rokeya Sultana Rekha; Hongmei Ren; Jun Ren; Weichao Ren; Tristan Renault; Giorgia Renga; Karen Reue; Kim Rewitz; Bruna Ribeiro de Andrade Ramos; S Amer Riazuddin; Teresa M Ribeiro-Rodrigues; Jean-Ehrland Ricci; Romeo Ricci; Victoria Riccio; Des R Richardson; Yasuko Rikihisa; Makarand V Risbud; Ruth M Risueño; Konstantinos Ritis; Salvatore Rizza; Rosario Rizzuto; Helen C Roberts; Luke D Roberts; Katherine J Robinson; Maria Carmela Roccheri; Stephane Rocchi; George G Rodney; Tiago Rodrigues; Vagner Ramon Rodrigues Silva; Amaia Rodriguez; Ruth Rodriguez-Barrueco; Nieves Rodriguez-Henche; Humberto Rodriguez-Rocha; Jeroen Roelofs; Robert S Rogers; Vladimir V Rogov; Ana I Rojo; Krzysztof Rolka; Vanina Romanello; Luigina Romani; Alessandra Romano; Patricia S Romano; David Romeo-Guitart; Luis C Romero; Montserrat Romero; Joseph C Roney; Christopher Rongo; Sante Roperto; Mathias T Rosenfeldt; Philip Rosenstiel; Anne G Rosenwald; Kevin A Roth; Lynn Roth; Steven Roth; Kasper M A Rouschop; Benoit D Roussel; Sophie Roux; Patrizia Rovere-Querini; Ajit Roy; Aurore Rozieres; Diego Ruano; David C Rubinsztein; Maria P Rubtsova; Klaus Ruckdeschel; Christoph Ruckenstuhl; Emil Rudolf; Rüdiger Rudolf; Alessandra Ruggieri; Avnika Ashok Ruparelia; Paola Rusmini; Ryan R Russell; Gian Luigi Russo; Maria Russo; Rossella Russo; Oxana O Ryabaya; Kevin M Ryan; Kwon-Yul Ryu; Maria Sabater-Arcis; Ulka Sachdev; Michael Sacher; Carsten Sachse; Abhishek Sadhu; Junichi Sadoshima; Nathaniel Safren; Paul Saftig; Antonia P Sagona; Gaurav Sahay; Amirhossein Sahebkar; Mustafa Sahin; Ozgur Sahin; Sumit Sahni; Nayuta Saito; Shigeru Saito; Tsunenori Saito; Ryohei Sakai; Yasuyoshi Sakai; Jun-Ichi Sakamaki; Kalle Saksela; Gloria Salazar; Anna Salazar-Degracia; Ghasem H Salekdeh; Ashok K Saluja; Belém Sampaio-Marques; Maria Cecilia Sanchez; Jose A Sanchez-Alcazar; Victoria Sanchez-Vera; Vanessa Sancho-Shimizu; J Thomas Sanderson; Marco Sandri; Stefano Santaguida; Laura Santambrogio; Magda M Santana; Giorgio Santoni; Alberto Sanz; Pascual Sanz; Shweta Saran; Marco Sardiello; Timothy J Sargeant; Apurva Sarin; Chinmoy Sarkar; Sovan Sarkar; Maria-Rosa Sarrias; Surajit Sarkar; Dipanka Tanu Sarmah; Jaakko Sarparanta; Aishwarya Sathyanarayan; Ranganayaki Sathyanarayanan; K Matthew Scaglione; Francesca Scatozza; Liliana Schaefer; Zachary T Schafer; Ulrich E Schaible; Anthony H V Schapira; Michael Scharl; Hermann M Schatzl; Catherine H Schein; Wiep Scheper; David Scheuring; Maria Vittoria Schiaffino; Monica Schiappacassi; Rainer Schindl; Uwe Schlattner; Oliver Schmidt; Roland Schmitt; Stephen D Schmidt; Ingo Schmitz; Eran Schmukler; Anja Schneider; Bianca E Schneider; Romana Schober; Alejandra C Schoijet; Micah B Schott; Michael Schramm; Bernd Schröder; Kai Schuh; Christoph Schüller; Ryan J Schulze; Lea Schürmanns; Jens C Schwamborn; Melanie Schwarten; Filippo Scialo; Sebastiano Sciarretta; Melanie J Scott; Kathleen W Scotto; A Ivana Scovassi; Andrea Scrima; Aurora Scrivo; David Sebastian; Salwa Sebti; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Iban Seiliez; Ekihiro Seki; Scott B Selleck; Frank W Sellke; Joshua T Selsby; Michael Sendtner; Serif Senturk; Elena Seranova; Consolato Sergi; Ruth Serra-Moreno; Hiromi Sesaki; Carmine Settembre; Subba Rao Gangi Setty; Gianluca Sgarbi; Ou Sha; John J Shacka; Javeed A Shah; Dantong Shang; Changshun Shao; Feng Shao; Soroush Sharbati; Lisa M Sharkey; Dipali Sharma; Gaurav Sharma; Kulbhushan Sharma; Pawan Sharma; Surendra Sharma; Han-Ming Shen; Hongtao Shen; Jiangang Shen; Ming Shen; Weili Shen; Zheni Shen; Rui Sheng; Zhi Sheng; Zu-Hang Sheng; Jianjian Shi; Xiaobing Shi; Ying-Hong Shi; Kahori Shiba-Fukushima; Jeng-Jer Shieh; Yohta Shimada; Shigeomi Shimizu; Makoto Shimozawa; Takahiro Shintani; Christopher J Shoemaker; Shahla Shojaei; Ikuo Shoji; Bhupendra V Shravage; Viji Shridhar; Chih-Wen Shu; Hong-Bing Shu; Ke Shui; Arvind K Shukla; Timothy E Shutt; Valentina Sica; Aleem Siddiqui; Amanda Sierra; Virginia Sierra-Torre; Santiago Signorelli; Payel Sil; Bruno J de Andrade Silva; Johnatas D Silva; Eduardo Silva-Pavez; Sandrine Silvente-Poirot; Rachel E Simmonds; Anna Katharina Simon; Hans-Uwe Simon; Matias Simons; Anurag Singh; Lalit P Singh; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Sudha B Singh; Sunaina Singh; Surinder Pal Singh; Debasish Sinha; Rohit Anthony Sinha; Sangita Sinha; Agnieszka Sirko; Kapil Sirohi; Efthimios L Sivridis; Panagiotis Skendros; Aleksandra Skirycz; Iva Slaninová; Soraya S Smaili; Andrei Smertenko; Matthew D Smith; Stefaan J Soenen; Eun Jung Sohn; Sophia P M Sok; Giancarlo Solaini; Thierry Soldati; Scott A Soleimanpour; Rosa M Soler; Alexei Solovchenko; Jason A Somarelli; Avinash Sonawane; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Kunhua Song; Zhiyin Song; Leandro R Soria; Maurizio Sorice; Alexander A Soukas; Sandra-Fausia Soukup; Diana Sousa; Nadia Sousa; Paul A Spagnuolo; Stephen A Spector; M M Srinivas Bharath; Daret St Clair; Venturina Stagni; Leopoldo Staiano; Clint A Stalnecker; Metodi V Stankov; Peter B Stathopulos; Katja Stefan; Sven Marcel Stefan; Leonidas Stefanis; Joan S Steffan; Alexander Steinkasserer; Harald Stenmark; Jared Sterneckert; Craig Stevens; Veronika Stoka; Stephan Storch; Björn Stork; Flavie Strappazzon; Anne Marie Strohecker; Dwayne G Stupack; Huanxing Su; Ling-Yan Su; Longxiang Su; Ana M Suarez-Fontes; Carlos S Subauste; Selvakumar Subbian; Paula V Subirada; Ganapasam Sudhandiran; Carolyn M Sue; Xinbing Sui; Corey Summers; Guangchao Sun; Jun Sun; Kang Sun; Meng-Xiang Sun; Qiming Sun; Yi Sun; Zhongjie Sun; Karen K S Sunahara; Eva Sundberg; Katalin Susztak; Peter Sutovsky; Hidekazu Suzuki; Gary Sweeney; J David Symons; Stephen Cho Wing Sze; Nathaniel J Szewczyk; Anna Tabęcka-Łonczynska; Claudio Tabolacci; Frank Tacke; Heinrich Taegtmeyer; Marco Tafani; Mitsuo Tagaya; Haoran Tai; Stephen W G Tait; Yoshinori Takahashi; Szabolcs Takats; Priti Talwar; Chit Tam; Shing Yau Tam; Davide Tampellini; Atsushi Tamura; Chong Teik Tan; Eng-King Tan; Ya-Qin Tan; Masaki Tanaka; Motomasa Tanaka; Daolin Tang; Jingfeng Tang; Tie-Shan Tang; Isei Tanida; Zhipeng Tao; Mohammed Taouis; Lars Tatenhorst; Nektarios Tavernarakis; Allen Taylor; Gregory A Taylor; Joan M Taylor; Elena Tchetina; Andrew R Tee; Irmgard Tegeder; David Teis; Natercia Teixeira; Fatima Teixeira-Clerc; Kumsal A Tekirdag; Tewin Tencomnao; Sandra Tenreiro; Alexei V Tepikin; Pilar S Testillano; Gianluca Tettamanti; Pierre-Louis Tharaux; Kathrin Thedieck; Arvind A Thekkinghat; Stefano Thellung; Josephine W Thinwa; V P Thirumalaikumar; Sufi Mary Thomas; Paul G Thomes; Andrew Thorburn; Lipi Thukral; Thomas Thum; Michael Thumm; Ling Tian; Ales Tichy; Andreas Till; Vincent Timmerman; Vladimir I Titorenko; Sokol V Todi; Krassimira Todorova; Janne M Toivonen; Luana Tomaipitinca; Dhanendra Tomar; Cristina Tomas-Zapico; Sergej Tomić; Benjamin Chun-Kit Tong; Chao Tong; Xin Tong; Sharon A Tooze; Maria L Torgersen; Satoru Torii; Liliana Torres-López; Alicia Torriglia; Christina G Towers; Roberto Towns; Shinya Toyokuni; Vladimir Trajkovic; Donatella Tramontano; Quynh-Giao Tran; Leonardo H Travassos; Charles B Trelford; Shirley Tremel; Ioannis P Trougakos; Betty P Tsao; Mario P Tschan; Hung-Fat Tse; Tak Fu Tse; Hitoshi Tsugawa; Andrey S Tsvetkov; David A Tumbarello; Yasin Tumtas; María J Tuñón; Sandra Turcotte; Boris Turk; Vito Turk; Bradley J Turner; Richard I Tuxworth; Jessica K Tyler; Elena V Tyutereva; Yasuo Uchiyama; Aslihan Ugun-Klusek; Holm H Uhlig; Marzena Ułamek-Kozioł; Ilya V Ulasov; Midori Umekawa; Christian Ungermann; Rei Unno; Sylvie Urbe; Elisabet Uribe-Carretero; Suayib Üstün; Vladimir N Uversky; Thomas Vaccari; Maria I Vaccaro; Björn F Vahsen; Helin Vakifahmetoglu-Norberg; Rut Valdor; Maria J Valente; Ayelén Valko; Richard B Vallee; Angela M Valverde; Greet Van den Berghe; Stijn van der Veen; Luc Van Kaer; Jorg van Loosdregt; Sjoerd J L van Wijk; Wim Vandenberghe; Ilse Vanhorebeek; Marcos A Vannier-Santos; Nicola Vannini; M Cristina Vanrell; Chiara Vantaggiato; Gabriele Varano; Isabel Varela-Nieto; Máté Varga; M Helena Vasconcelos; Somya Vats; Demetrios G Vavvas; Ignacio Vega-Naredo; Silvia Vega-Rubin-de-Celis; Guillermo Velasco; Ariadna P Velázquez; Tibor Vellai; Edo Vellenga; Francesca Velotti; Mireille Verdier; Panayotis Verginis; Isabelle Vergne; Paul Verkade; Manish Verma; Patrik Verstreken; Tim Vervliet; Jörg Vervoorts; Alexandre T Vessoni; Victor M Victor; Michel Vidal; Chiara Vidoni; Otilia V Vieira; Richard D Vierstra; Sonia Viganó; Helena Vihinen; Vinoy Vijayan; Miquel Vila; Marçal Vilar; José M Villalba; Antonio Villalobo; Beatriz Villarejo-Zori; Francesc Villarroya; Joan Villarroya; Olivier Vincent; Cecile Vindis; Christophe Viret; Maria Teresa Viscomi; Dora Visnjic; Ilio Vitale; David J Vocadlo; Olga V Voitsekhovskaja; Cinzia Volonté; Mattia Volta; Marta Vomero; Clarissa Von Haefen; Marc A Vooijs; Wolfgang Voos; Ljubica Vucicevic; Richard Wade-Martins; Satoshi Waguri; Kenrick A Waite; Shuji Wakatsuki; David W Walker; Mark J Walker; Simon A Walker; Jochen Walter; Francisco G Wandosell; Bo Wang; Chao-Yung Wang; Chen Wang; Chenran Wang; Chenwei Wang; Cun-Yu Wang; Dong Wang; Fangyang Wang; Feng Wang; Fengming Wang; Guansong Wang; Han Wang; Hao Wang; Hexiang Wang; Hong-Gang Wang; Jianrong Wang; Jigang Wang; Jiou Wang; Jundong Wang; Kui Wang; Lianrong Wang; Liming Wang; Maggie Haitian Wang; Meiqing Wang; Nanbu Wang; Pengwei Wang; Peipei Wang; Ping Wang; Ping Wang; Qing Jun Wang; Qing Wang; Qing Kenneth Wang; Qiong A Wang; Wen-Tao Wang; Wuyang Wang; Xinnan Wang; Xuejun Wang; Yan Wang; Yanchang Wang; Yanzhuang Wang; Yen-Yun Wang; Yihua Wang; Yipeng Wang; Yu Wang; Yuqi Wang; Zhe Wang; Zhenyu Wang; Zhouguang Wang; Gary Warnes; Verena Warnsmann; Hirotaka Watada; Eizo Watanabe; Maxinne Watchon; Anna Wawrzyńska; Timothy E Weaver; Grzegorz Wegrzyn; Ann M Wehman; Huafeng Wei; Lei Wei; Taotao Wei; Yongjie Wei; Oliver H Weiergräber; Conrad C Weihl; Günther Weindl; Ralf Weiskirchen; Alan Wells; Runxia H Wen; Xin Wen; Antonia Werner; Beatrice Weykopf; Sally P Wheatley; J Lindsay Whitton; Alexander J Whitworth; Katarzyna Wiktorska; Manon E Wildenberg; Tom Wileman; Simon Wilkinson; Dieter Willbold; Brett Williams; Robin S B Williams; Roger L Williams; Peter R Williamson; Richard A Wilson; Beate Winner; Nathaniel J Winsor; Steven S Witkin; Harald Wodrich; Ute Woehlbier; Thomas Wollert; Esther Wong; Jack Ho Wong; Richard W Wong; Vincent Kam Wai Wong; W Wei-Lynn Wong; An-Guo Wu; Chengbiao Wu; Jian Wu; Junfang Wu; Kenneth K Wu; Min Wu; Shan-Ying Wu; Shengzhou Wu; Shu-Yan Wu; Shufang Wu; William K K Wu; Xiaohong Wu; Xiaoqing Wu; Yao-Wen Wu; Yihua Wu; Ramnik J Xavier; Hongguang Xia; Lixin Xia; Zhengyuan Xia; Ge Xiang; Jin Xiang; Mingliang Xiang; Wei Xiang; Bin Xiao; Guozhi Xiao; Hengyi Xiao; Hong-Tao Xiao; Jian Xiao; Lan Xiao; Shi Xiao; Yin Xiao; Baoming Xie; Chuan-Ming Xie; Min Xie; Yuxiang Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Congfeng Xu; En Xu; Haoxing Xu; Jing Xu; JinRong Xu; Liang Xu; Wen Wen Xu; Xiulong Xu; Yu Xue; Sokhna M S Yakhine-Diop; Masamitsu Yamaguchi; Osamu Yamaguchi; Ai Yamamoto; Shunhei Yamashina; Shengmin Yan; Shian-Jang Yan; Zhen Yan; Yasuo Yanagi; Chuanbin Yang; Dun-Sheng Yang; Huan Yang; Huang-Tian Yang; Hui Yang; Jin-Ming Yang; Jing Yang; Jingyu Yang; Ling Yang; Liu Yang; Ming Yang; Pei-Ming Yang; Qian Yang; Seungwon Yang; Shu Yang; Shun-Fa Yang; Wannian Yang; Wei Yuan Yang; Xiaoyong Yang; Xuesong Yang; Yi Yang; Ying Yang; Honghong Yao; Shenggen Yao; Xiaoqiang Yao; Yong-Gang Yao; Yong-Ming Yao; Takahiro Yasui; Meysam Yazdankhah; Paul M Yen; Cong Yi; Xiao-Ming Yin; Yanhai Yin; Zhangyuan Yin; Ziyi Yin; Meidan Ying; Zheng Ying; Calvin K Yip; Stephanie Pei Tung Yiu; Young H Yoo; Kiyotsugu Yoshida; Saori R Yoshii; Tamotsu Yoshimori; Bahman Yousefi; Boxuan Yu; Haiyang Yu; Jun Yu; Jun Yu; Li Yu; Ming-Lung Yu; Seong-Woon Yu; Victor C Yu; W Haung Yu; Zhengping Yu; Zhou Yu; Junying Yuan; Ling-Qing Yuan; Shilin Yuan; Shyng-Shiou F Yuan; Yanggang Yuan; Zengqiang Yuan; Jianbo Yue; Zhenyu Yue; Jeanho Yun; Raymond L Yung; David N Zacks; Gabriele Zaffagnini; Vanessa O Zambelli; Isabella Zanella; Qun S Zang; Sara Zanivan; Silvia Zappavigna; Pilar Zaragoza; Konstantinos S Zarbalis; Amir Zarebkohan; Amira Zarrouk; Scott O Zeitlin; Jialiu Zeng; Ju-Deng Zeng; Eva Žerovnik; Lixuan Zhan; Bin Zhang; Donna D Zhang; Hanlin Zhang; Hong Zhang; Hong Zhang; Honghe Zhang; Huafeng Zhang; Huaye Zhang; Hui Zhang; Hui-Ling Zhang; Jianbin Zhang; Jianhua Zhang; Jing-Pu Zhang; Kalin Y B Zhang; Leshuai W Zhang; Lin Zhang; Lisheng Zhang; Lu Zhang; Luoying Zhang; Menghuan Zhang; Peng Zhang; Sheng Zhang; Wei Zhang; Xiangnan Zhang; Xiao-Wei Zhang; Xiaolei Zhang; Xiaoyan Zhang; Xin Zhang; Xinxin Zhang; Xu Dong Zhang; Yang Zhang; Yanjin Zhang; Yi Zhang; Ying-Dong Zhang; Yingmei Zhang; Yuan-Yuan Zhang; Yuchen Zhang; Zhe Zhang; Zhengguang Zhang; Zhibing Zhang; Zhihai Zhang; Zhiyong Zhang; Zili Zhang; Haobin Zhao; Lei Zhao; Shuang Zhao; Tongbiao Zhao; Xiao-Fan Zhao; Ying Zhao; Yongchao Zhao; Yongliang Zhao; Yuting Zhao; Guoping Zheng; Kai Zheng; Ling Zheng; Shizhong Zheng; Xi-Long Zheng; Yi Zheng; Zu-Guo Zheng; Boris Zhivotovsky; Qing Zhong; Ao Zhou; Ben Zhou; Cefan Zhou; Gang Zhou; Hao Zhou; Hong Zhou; Hongbo Zhou; Jie Zhou; Jing Zhou; Jing Zhou; Jiyong Zhou; Kailiang Zhou; Rongjia Zhou; Xu-Jie Zhou; Yanshuang Zhou; Yinghong Zhou; Yubin Zhou; Zheng-Yu Zhou; Zhou Zhou; Binglin Zhu; Changlian Zhu; Guo-Qing Zhu; Haining Zhu; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Yanping Zhu; Yushan Zhu; Haixia Zhuang; Xiaohong Zhuang; Katarzyna Zientara-Rytter; Christine M Zimmermann; Elena Ziviani; Teresa Zoladek; Wei-Xing Zong; Dmitry B Zorov; Antonio Zorzano; Weiping Zou; Zhen Zou; Zhengzhi Zou; Steven Zuryn; Werner Zwerschke; Beate Brand-Saberi; X Charlie Dong; Chandra Shekar Kenchappa; Zuguo Li; Yong Lin; Shigeru Oshima; Yueguang Rong; Judith C Sluimer; Christina L Stallings; Chun-Kit Tong
Journal:  Autophagy       Date:  2021-02-08       Impact factor: 13.391

Review 9.  Autophagy, autophagy-associated adaptive immune responses and its role in hematologic malignancies.

Authors:  Liangshun You; Shenhe Jin; Li Zhu; Wenbin Qian
Journal:  Oncotarget       Date:  2017-02-14

10.  Interplay between apoptosis and autophagy in colorectal cancer.

Authors:  Hao-Ran Qian; Zhao-Qi Shi; He-Pan Zhu; Li-Hu Gu; Xian-Fa Wang; Yi Yang
Journal:  Oncotarget       Date:  2017-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.